BioLargo (BLGO) 10-K 1 Apr 24 2023 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2023	Mar. 29, 2024	Jun. 30, 2023
Document Information [Line Items]
Entity Central Index Key	0000880242
Entity Registrant Name	BIOLARGO, INC.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2023
Document Transition Report	false
Entity File Number	000-19709
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	65-0159115
Entity Address, Address Line One	14921 Chestnut St.
Entity Address, City or Town	Westminster
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92683
City Area Code	888
Local Phone Number	400-2863
Title of 12(b) Security	Common Stock
Trading Symbol	BLGO
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 40,905,542
Entity Common Stock, Shares Outstanding		295,552,937
Auditor Firm ID	400
Auditor Name	HACKER, JOHNSON & SMITH PA
Auditor Location	Tampa, Florida

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 3,539,000	$ 1,851,000
Accounts receivable, net of allowance	2,612,000	1,064,000
Inventories, net of allowance	153,000	120,000
Prepaid expenses and other current assets	58,000	118,000
Total current assets	6,362,000	3,153,000
Equipment and leasehold improvements, net of depreciation	662,000	287,000
Other non-current assets	70,000	124,000
Investment in South Korean joint venture	19,000	33,000
Right of use, operating lease, net of amortization	1,092,000	867,000
Clyra Medical prepaid marketing (Note 10)	0	394,000
Total assets	8,205,000	4,858,000
Current liabilities:
Total	1,488,000	940,000
Contract liabilities	303,000	17,000
Lease liabilities	105,000	97,000
Deposits	117,000	184,000
Total current liabilities	2,710,000	1,576,000
Long-term liabilities:
Long-Term Debt, Excluding Current Maturities	289,000	237,000
Lease liability, net of current	1,004,000	773,000
Total long-term liabilities	1,293,000	1,271,000
Total liabilities	4,003,000	2,847,000
CONTINGENCIES (Note 1)
STOCKHOLDERS’ EQUITY:
Preferred Series A, $0.00067 par value, 50,000,000 shares authorized, no shares issued and outstanding, at December 31, 2023 and December 31, 2022	0	0
Common stock, $0.00067 par value, 400,000,000 shares authorized, 292,945,747 and 278,462,706 shares issued and outstanding, at December 31, 2023 and December 31, 2022	196,000	186,000
Additional paid-in capital	154,023,000	148,435,000
Accumulated deficit	(147,098,000)	(143,594,000)
Accumulated other comprehensive loss	(277,000)	(149,000)
Total BioLargo Inc. and subsidiaries stockholders’ equity	6,844,000	4,878,000
Non-controlling interest (Note 9, 10 and 11)	(2,642,000)	(2,867,000)
Total stockholders’ equity	4,202,000	2,011,000
Total liabilities and stockholders’ equity	8,205,000	4,858,000
Debt Obligations [Member]
Current liabilities:
Long term debt	66,000	100,000
Entities, Excluding Partially Owned Subsidiary [Member]
Current liabilities:
Total	1,488,000	940,000
Partially Owned Subsidiary [Member]
Current liabilities:
Total	397,000	238,000
Long-term liabilities:
Long-Term Debt, Excluding Current Maturities	0	261,000
Clyra Medical Debt Obligations [Member]
Current liabilities:
Long term debt	$ 234,000	$ 0

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2023	Dec. 31, 2022
Convertible Preferred Stock, Par Value (in dollars per share)	$ 0.00067	$ 0.00067
Convertible Preferred Stock, Shares Authorized (in shares)	50,000,000	50,000,000
Convertible Preferred Stock, Shares Issued (in shares)	0	0
Convertible Preferred Stock, Shares Outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.00067	$ 0.00067
Common stock, shares authorized (in shares)	400,000,000	400,000,000
Common stock, shares issued (in shares)	292,945,747	278,462,706
Common stock, shares outstanding (in shares)	292,945,747	278,462,706

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue	$ 12,230,000	$ 5,884,000
Cost of revenue
Cost of Goods and Services Sold	(6,076,000)	(3,027,000)
Gross profit	6,154,000	2,857,000
Operating expenses:
Selling, general and administrative expenses	8,058,000	6,731,000
Research and development	2,282,000	1,319,000
Impairment expense	394,000	197,000
Total operating expenses	10,734,000	8,247,000
Operating loss	(4,580,000)	(5,390,000)
Other income (expense):
PPP forgiveness	0	174,000
Grant income	36,000	74,000
Tax credit (expense) income	(13,000)	63,000
Interest expense	(91,000)	(53,000)
Total other income	(68,000)	258,000
Net loss	(4,648,000)	(5,132,000)
Net loss attributable to noncontrolling interest	(1,144,000)	(659,000)
Net loss attributable to common stockholders	$ (3,504,000)	$ (4,473,000)
Net loss per share attributable to common stockholders:
Loss per share attributable to stockholders – basic and diluted (in dollars per share)	$ (0.02)	$ (0.02)
Weighted average number of shares of common stock outstanding: (in shares)	285,956,852	268,302,234
Comprehensive loss attributable to common stockholders:
Net loss	$ (4,648,000)	$ (5,132,000)
Foreign currency translation adjustment	(128,000)	(34,000)
Comprehensive loss	(4,776,000)	(5,166,000)
Comprehensive loss attributable to noncontrolling interest	(1,144,000)	(659,000)
Comprehensive loss attributable to common stockholders	(3,632,000)	(4,507,000)
Product [Member]
Revenue	11,460,000	4,434,000
Cost of revenue
Cost of Goods and Services Sold	(5,681,000)	(2,177,000)
Service [Member]
Revenue	770,000	1,450,000
Cost of revenue
Cost of Goods and Services Sold	$ (395,000)	$ (850,000)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($)	Clyra Medical Technologies [Member] Common Stock [Member]	Clyra Medical Technologies [Member] Additional Paid-in Capital [Member]	Clyra Medical Technologies [Member] Retained Earnings [Member]	Clyra Medical Technologies [Member] AOCI Attributable to Parent [Member]	Clyra Medical Technologies [Member] Noncontrolling Interest [Member]	Clyra Medical Technologies [Member]	BioLargo Energy Technologies, Inc (BETI) [Member] Common Stock [Member]	BioLargo Energy Technologies, Inc (BETI) [Member] Additional Paid-in Capital [Member]	BioLargo Energy Technologies, Inc (BETI) [Member] Retained Earnings [Member]	BioLargo Energy Technologies, Inc (BETI) [Member] AOCI Attributable to Parent [Member]	BioLargo Energy Technologies, Inc (BETI) [Member] Noncontrolling Interest [Member]	BioLargo Energy Technologies, Inc (BETI) [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2021													255,893,726
Balance at Dec. 31, 2021													$ 171,000	$ 143,718,000	$ (139,121,000)	$ (115,000)	$ (3,720,000)	$ 933,000
Stock for cash (in shares)													19,580,225
Sale of stock for cash													$ 13,000	3,604,000	0	0	0	3,617,000
Stock issued as commitment fee (in shares)													1,250,000
Stock issued as commitment fee													$ 1,000	(1,000)	0	0	0	$ 0
Stock for service (in shares)													1,448,512					1,448,512
Issuance of common stock for services													$ 1,000	290,000	0	0	0	$ 291,000
Stock option exercise (in shares)													290,243
Stock option exercise													$ 0	40,000	0	0	0	40,000
Stock option expense													0	1,663,000	0	0	0	1,663,000
Noncontrolling interest allocation													0	(1,287,000)	0	0	1,287,000	0
Clyra stock option expense	$ 0	$ 408,000	$ 0	$ 0	$ 0	$ 408,000
Clyra preferred stock offering	0	0	0	0	225,000	225,000
Net loss													0	0	(4,473,000)	0	(659,000)	(5,132,000)
Foreign currency translation													$ 0	0	0	(34,000)	0	(34,000)
Balance (in shares) at Dec. 31, 2022													278,462,706
Balance at Dec. 31, 2022													$ 186,000	148,435,000	(143,594,000)	(149,000)	(2,867,000)	2,011,000
Stock for cash (in shares)													12,003,517
Sale of stock for cash													$ 8,000	2,145,000	0	0	0	$ 2,153,000
Stock for service (in shares)													1,951,541					1,951,541
Issuance of common stock for services													$ 2,000	382,000	0	0	0	$ 384,000
Stock option exercise	0	3,000	0	0	0	3,000
Stock option expense													0	1,864,000	0	0	0	1,864,000
Noncontrolling interest allocation													0	904,000	0	0	(904,000)	0
Clyra stock option expense	0	260,000	0	0	0	260,000
Clyra preferred stock offering	0	0	0	0	1,575,000	1,575,000
Net loss													0	0	(3,504,000)	0	(1,144,000)	(4,648,000)
Foreign currency translation													$ 0	0	0	(128,000)	0	(128,000)
Stock share exchange - VB (in shares)													527,983
Warrant Interest													$ 0	30,000	0	0	0	30,000
Common unit offering	0	0	0	0	35,000	35,000	$ 0	$ 0	$ 0	$ 0	$ 905,000	$ 905,000
Clyra Preferred Series A dividend	$ 0	$ 0	$ 0	$ 0	$ (242,000)	$ (242,000)
Balance (in shares) at Dec. 31, 2023													292,945,747
Balance at Dec. 31, 2023													$ 196,000	$ 154,023,000	$ (147,098,000)	$ (277,000)	$ (2,642,000)	$ 4,202,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities:
Net loss	$ (4,648,000)	$ (5,132,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock option compensation expense	2,124,000	2,071,000
Common stock issued for services	384,000	291,000
Impairment, Long-Lived Asset, Held-for-Use	394,000	197,000
Inventory reserve	54,000	158,000
Amortization of right-of-use operating lease assets	169,000	0
Interest expense related to amortization of the discount on convertible notes payable	3,000	17,000
Fair value of warrants issued for interest	30,000	0
Loss on investment in South Korean joint venture	14,000	15,000
PPP forgiveness	0	(174,000)
Amortization and depreciation expense	103,000	45,000
Bad debt expense	85,000	0
Changes in assets and liabilities:
Accounts receivable	(1,633,000)	(551,000)
Inventories	(89,000)	(35,000)
Contract liabilities	286,000	(72,000)
Prepaid expenses and other assets	116,000	(90,000)
Lease liability, net	(155,000)	3,000
Deposits	(67,000)	105,000
Net cash used in operating activities	(2,365,000)	(2,762,000)
Cash flows from investing activities:
Equipment purchases	(478,000)	(271,000)
Net cash used in investing activities	(478,000)	(271,000)
Cash flows from financing activities:
Proceeds from sale of common stock	2,153,000	3,617,000
Proceeds from Clyra Medical stock option exercise	0	40,000
Proceeds from debt obligation, net	65,000	0
Repayment by Clyra Medical on debt obligation	(27,000)	(26,000)
Proceeds from sale of preferred stock in Clyra Medical	1,575,000	225,000
Proceeds from Clyra Medical note payable	0	100,000
Net cash provided by financing activities	4,659,000	3,956,000
Net effect of foreign currency translation	(128,000)	(34,000)
Net change in cash	1,688,000	889,000
Cash and cash equivalent at beginning of year	1,851,000	962,000
Cash and cash equivalent at end of year	3,539,000	1,851,000
Supplemental disclosures of cash flow information
Interest	58,000	36,000
Income taxes	0	3,000
Short-term lease payments not included in lease liability	52,000	99,000
Non-cash investing and financing activities:
BioLargo debt obligations exchanged for BETI noncontrolling interest	50,000	0
Fair value of common stock issued to Lincoln Park as finance fee	0	240,000
Present value of new operating right of use and lease liability	394,000	443,000
Conversion of Intercompany Receivable into Clyra Shares [Member]
Non-cash investing and financing activities:
Allocation of stock option expense within noncontrolling interest	904,000	1,287,000
Series A Preferred Stock [Member]
Non-cash investing and financing activities:
Clyra preferred series A dividend	242,000	0
Clyra Medical Common Stock [Member]
Cash flows from financing activities:
Proceeds from sale of common stock	35,000	0
Proceeds from Clyra Medical stock option exercise	3,000	0
BETI Common Stock [Member]
Cash flows from financing activities:
Proceeds from sale of common stock	855,000	0
Entities, Excluding Partially Owned Subsidiary [Member]
Changes in assets and liabilities:
Accounts payable and accrued expenses	548,000	382,000
Partially Owned Subsidiary [Member]
Changes in assets and liabilities:
Accounts payable and accrued expenses	$ (83,000)	$ 8,000

Insider Trading Arrangements

Insider Trading Arrangements	12 Months Ended
	Dec. 31, 2023
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]	9B. OTHER INFORMATION None
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Note 1 - Business and Organizat

Note 1 - Business and Organization	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1 . Business and Organization Description of Business BioLargo, Inc. (“BioLargo”, or the “Company”) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination (per- and polyfluoroalkyl substances), advanced water and wastewater treatment, industrial odor control, air quality control, infection control, and myriad environmental remediation challenges. Our business strategy is straightforward: we invent or acquire technologies that we believe have the potential to be disruptive in large commercial markets; we develop and validate these technologies to advance and promote their commercial success as we leverage our considerable scientific, engineering, and entrepreneurial talent; we then monetize these technical assets through a variety of business structures that may Liquidity / Going concern The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of our business. During the year ended December 31, 2023 12 December 31, 2023 not 3 3 6 10 4 We intend to reinvest available cash into business operations and intend to continue to seek further investment capital for the remainder of this year. We have been, and anticipate that we will continue to be, limited in terms of our capital resources. If we are unable to rely on our current arrangement with Lincoln Park to fund our working capital requirements, we will have to rely on other forms of financing, and there is no The foregoing factors raise substantial doubt about our ability to continue as a going concern, unless we are able to continue to raise funds through stock sales to Lincoln Park or other private financings, and in the long term, our ability to attain a reasonable threshold of operating efficiencies and achieve profitable operations by licensing or otherwise commercializing products incorporating our technologies. The consolidated financial statements do not Organization We are a Delaware corporation formed in 1991. 2006; 2009; 2022; 2014; 2016. 9 2019, 10 2012 2023, 11 2017. 2,

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 2 . Summary of Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of the Company, its wholly-owned subsidiaries, and partially-owned subsidiaries. All intercompany accounts and transactions have been eliminated. Foreign Currency The Company has designated the functional currency of BioLargo Canada to be the Canadian dollar. Therefore, translation gains and losses resulting from differences in exchange rates are recorded in accumulated other comprehensive loss. Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three one $250,000 not As of December 31, 2023 2022 December 31, 2023 December 31, 2022 BioLargo, Inc. and subsidiaries $ 3,142 $ 1,685 Clyra Medical Technologies, Inc. 397 166 Total $ 3,539 $ 1,851 Accounts Receivable In June 2016, 2016 13, January 1, 2023 Accounts receivable are customer obligations that are unconditional. Accounts receivable are presented net of an allowance for doubtful accounts for expected credit losses, which represents an estimate of amounts that may not no not December 31, 2023, December 31, 2022, December 31, 2023, Credit Concentration We have a limited number of customers that account for significant portions of our revenue. During the year ended December 31, 2023 one December 31, 2022 two December 31, 2023 December 31, 2022 Customer A 82 % 47 % Customer B <10 % 10 % We had one December 31, 2023 2022 , December 31, 2023 December 31, 2022 Customer A 68 % 24 % Inventory Inventories are stated at the lower of cost or net realizable value using the average cost method. The allowance for obsolete inventory as of December 31, 2023 2022 December 31, 2023 December 31, 2022 Raw material $ 79 $ 46 Finished goods 74 74 Total $ 153 $ 120 Other Non-Current Assets Other non-current assets consisted of (i) security deposits related to our business offices, (ii) three October 22, 2021 , 2022 2022 2023, 2023, not not December 31, 2023 December 31, 2022 Patents $ 34 $ 34 Security deposits 36 36 Tax credit receivable — 54 Total $ 70 $ 124 Equity Method of Accounting On March 20, 2020 , We account for our investment in the joint venture under the equity method of accounting. We have determined that while we have significant influence over the joint venture through our technology license and our position on the Board of Directors, we do not December 31, 2023 2022 , Impairment Long-lived and definite lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not For the year ended December 31, 2023 , 10 December 31, 2023 2022 Loss Per Share We report basic and diluted loss per share (“LPS”) for common and common share equivalents. Basic LPS is computed by dividing reported earnings by the weighted average shares outstanding. Diluted LPS is computed by adding to the weighted average shares the dilutive effect if convertible notes payable, stock options and warrants were exercised into common stock. For the years ended December 31, 2023 2022 , Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and revenues and expenses during the year reported. Actual results could differ from those estimates. Estimates are used when accounting for stock-based transactions, debt transactions, derivative liabilities, allowance for bad debt, asset depreciation and amortization, impairment expense, among others. The methods, estimates and judgments we use in applying these most critical accounting policies have a significant impact on the results of our consolidated financial statements. Share-Based Compensation Expense We recognize compensation expense for stock option awards on a straight-line basis over the applicable service period of the award, which is the vesting period. Fair value is determined on the grant date. Share-based compensation expense is based on the grant date fair value estimated using the Black-Scholes Option Pricing Model. For stock and stock options issued to consultants and other non-employees for services, the Company measures and records an expense as of the earlier of the date at which either: a commitment for performance by the non-employee has been reached or the non-employee’s performance is complete. The equity instruments are measured at the current fair value, and for stock options, the instruments are measured at fair value using the Black Scholes option model. The following methodology and assumptions were used to calculate share-based compensation for the years ended December 31, 2023 2022 : 2023 2022 Non Plan 2018 Plan Non Plan 2018 Plan Risk free interest rate 3.48 - 3.58 % 3.48 - 4.45 % 2.32 - 3.83 % 2.32 - 3.83 % Expected volatility 114 % 102 - 114 % 114 - 117 % 114 - 117 % Expected dividend yield — — — — Forfeiture rate — — — — Life in years 10 10 10 10 Expected price volatility is the measure by which our stock price is expected to fluctuate during the expected term of an option. Expected volatility is derived from the historical daily change in the market price of our common stock, as we believe that historical volatility is the best indicator of future volatility. The risk-free interest rate used in the Black-Scholes calculation is based on the prevailing U.S. Treasury yield as determined by the U.S. Federal Reserve. We have never paid any cash dividends on our common stock and do not Warrants Warrants issued with our convertible and non-convertible debt instruments are accounted for under the fair value and relative fair value method. The warrant is first not . not If the warrant is determined to not Convertible debt instruments are recorded at fair value, limited to a relative fair value based upon the percentage of its fair value to the total fair value including the fair value of the warrant. The warrant relative fair values are also recorded as a discount to the convertible promissory notes. As present, these equity features of the convertible promissory notes have recorded a discount to the convertible notes that is substantially equal to the proceeds received. Non-Cash Transactions We have established a policy relative to the methodology to determine the value assigned to each intangible we acquire, and/or services or products received for non-cash consideration of our common stock. The value is based on the market price of our common stock issued as consideration, at the date of the agreement of each transaction or when the service is rendered or product is received. Revenue Recognition We account for revenue in accordance with ASC 606 , Step 1: Step 2: Step 3: Step 4: Step 5: The Company’s products are sold through a contract with the customer and a written purchase order, in which the details of the contract are defined including the transaction price and method of shipment. The only performance obligation is to create and ship the product, and each product has separate pricing. Revenue is recognized at a point in time when the goods are shipped if the agreement is FOB manufacturer, and when goods are delivered if FOB destination. Revenue is recognized with a reduction for sales discounts, as appropriate and negotiated in the customer’s purchase order. Service contracts are performed through a written contract, which specifies the performance obligations and the rate at which the services will be billed, typically by time and materials. Each service is separately negotiated and priced. Revenue is recognized as services are performed and completed, or, for services related to product installations, at the completion of the installation. A few contracts have called for milestone or fixed cost payments, where we invoice an agreed-to amount per month for the life of the contract. In these instances, completed work, billed hourly, is recognized as revenue. If the billing amount is greater or lesser than the completed work, a receivable or payable is created. These accounts are adjusted upon additional billings as the work is completed. To date, there have been no The Company has outstanding contract liability obligations of $303,000 and $17,000 as of December 31, 2023, 2022, December 31, 2023, 2022, $113,000 December 31, 2023, 2022, $71,000, not As we generate revenues from royalties or license fees from our intellectual property, a licensee will pay a license fee in one third Government Grants We have been awarded multiple research grants from the private and public Canadian research programs. Income we receive directly from grants is recorded as other income. We have been awarded over 80 first 2 015 . third third six eighteen not The grants typically provide for (i) recurring monthly amounts, (ii) reimbursement of costs for research talent for which we invoice to request payment, and (iii) ancillary cost reimbursement for research talent travel related costs. All awarded grants have specific requirements on how the money is spent, typically to employ researchers. None may Not no Income Taxes The asset and liability approach is used to recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of asset and liabilities. Deferred tax assets and liabilities are determined based on the differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect on deferred tax asset and liabilities of a change in tax rates is recognized in operations in the year that includes the enactment date. We account for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. Under GAAP, the tax effects of a position are recognized only if it is “more-likely-than- not” not not” no December 31, 2023 2022 . The Company assessed its earnings history, trends and estimates of future earnings and determined that the deferred tax asset could not December 31, 2023 . The Company recognizes interest and penalties on income taxes as a component of income tax expense, should such an expense be realized. Fair Value of Financial Instruments Management believes the carrying amounts of the Company’s financial instruments as of December 31, 2023 2022 Tax Credits Our research and development activities in Canada may not not Leases At inception of a lease contract, we assess whether the contract is, or contains, a lease. Our assessment is based on: ( 1 2 3 not no not not 12 not December 31, 2023 2022, December 31, 2023 2022, Equipment Equipment and leasehold improvements is stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range from 3 - 10 years. Additions, renewals, and betterments that significantly extend the life of the asset are capitalized. Expenditures for repairs and maintenance are charged to expense as incurred. For assets sold or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the accounts, and any related gain or loss is reflected in income for the period. Noncontrolling Interest A noncontrolling interest is defined as the portion of the equity in an entity not not 810 10 20, three December 31, 2023 2022. December 31, 2023, 2022, December 31, 2023. 2023. Recent Accounting Pronouncements In November 2023, 2023 07, 280 1. Require that a public entity disclose, on an annual and interim basis, significant segment expenses that are regularly provided to the chief operating decision maker (CODM) and included within each reported measure of segment profit or loss (collectively referred to as the “significant expense principle”). 2. Require that a public entity disclose, on an annual and interim basis, an amount for other segment items by reportable segment and a description of its composition. The other segment items category is the difference between segment revenue less the segment expenses disclosed under the significant expense principle and each reported measure of segment profit or loss. 3. Require that a public entity provide all annual disclosures about a reportable segment’s profit or loss and assets currently required by Topic 280 4. Clarify that if the CODM uses more than one may one 5. Require that a public entity disclose the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. 6. Require that a public entity that has a single reportable segment provide all the disclosures required by the amendments in this Update and all existing segment disclosures in Topic 280. This Update is effective for fiscal years beginning after December 15, 2023, December 15, 2024. December 31, 2023 no 12

Note 3 - Sale of Stock for Cash

Note 3 - Sale of Stock for Cash	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Stock Purchase Agreement [Text Block]	Note 3 . Sale of Stock for Cash Lincoln Park Financing On December 13, 2022, “2022 three may three 12 no first 2022 1 December 23, 2022. January 19, 2023. 2022 During the years ended December 31, 2023 2022, $1,253,000, Unit Offerings During the year ended December 31, 2023, 2022 $2,364,000, six five 6,

Note 4 - Debt Obligations

Note 4 - Debt Obligations	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 4 . Debt Obligations The following table summarizes our debt obligations outstanding as of December 31, 2023 2022 not 10 , December 31, 2023 2022 Current portion of debt: SBA Paycheck Protection Program loan $ 43 $ 43 Vehicle loan, current portion 13 — Convertible note payable, matures March 1, 2023 — 50 SBA EIDL Loan, matures July 2053, current portion 10 10 Debt discount, net of amortization — (3 ) Total current portion of debt $ 66 $ 100 Long-term debt: SBA Paycheck Protection Program loans, matures May 2025 $ 97 $ 97 Vehicle loan, matures March 2029 55 — SBA EIDL Loan, matures July 2053 137 140 Total long-term debt, net of current $ 289 $ 237 Total $ 355 $ 337 For the years ended December 31, 2023 2022 , Convertible note payable, matures March 1, 2023 On March 6, 2023, five 6 SBA Program Loans On February 7, 2022, December 31, 2023, On May 12, 2022, May 2025. In July 2020, July 2053.

Note 5 - Share-based Compensati

Note 5 - Share-based Compensation	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Compensation and Employee Benefit Plans [Text Block]	Note 5 . Share-Based Compensation Issuance of Common Stock in exchange for Services During the years ended December 31, 2023, 2022, third Payment of Officer Salaries During the year ended December 31, 2023, December 31, 2023, September 30, 2023, June 30, 2023, March 31, 2023, During the year ended December 31, 2022, September 30, 2022, $0.27; June 30, 2022, Payment of Consultant Fees During 2023, December 31, 2023, September 30, 2023, June 30, 2023, March 31, 2023, During 2022 , December 30, 2022 , September 30, 2022 , $0.27; June 30, 2022 , $0.18; March 31, 2022 , All of these offerings and sales were made in reliance on the exemption from registration contained in Section 4 2 not Stock Option Expense During the years ended December 31, 2023 2022 , 2018 December 31, 2023, 2022, 10 2018 On June 22, 2018 , 2018 “2018 may June 22, 2028 . 2018 2018 January 1 st December 31, 2023 , Activity for our stock options under the 2018 December 31, 2023 , December 31, 2022 , Weighted Weighted average average Aggregate Options exercise price per remaining intrinsic outstanding share Term value(1) Balance, December 31, 2021 23,186,142 $ 0.19 Granted 6,322,233 $ 0.22 Exercised (290,243 ) $ 0.16 Expired (733,583 ) $ 0.33 Balance, December 31, 2022 28,484,549 $ 0.19 Granted 12,623,899 $ 0.17 Balance, December 31, 2023 41,108,448 $ 0.19 7.7 Non-vested (5,067,958 ) $ 0.18 Vested, December 31, 2023 36,040,490 $ 0.19 7.7 $ 287,000 ( 1 December 31, 2023 . The options granted to purchase 12,623,899 shares during the year ended December 31, 2023 $151,000; $365,000; four As of December 31, 2023, The options granted to purchase 6,322,233 shares during the year ended December 31, 2022, $97,000; $401,000; four Chief Financial Officer Contract Extension On March 21, 2023, February 1, 2008 ( March 21, 2023 ( one January 31, 2024 ( 12 March 21, 2023, March 31, 2023, March 21, 2023, ten 2018 On March 22, 2022 , February 1, 2008 ( March 22, 2022 ( one January 31, 2023 ( 12 March 22, 2022 , March 22, 2022 , March 22, 2022 , ten 2018 2007 On September 7, 2007 , April 29, 2011 , 2007 “2007 may September 7, 2017 . September 2017 , Activity for our stock options under the 2007 December 31, 2023 2022 Weighted Weighted average average Aggregate Options exercise price remaining intrinsic outstanding per share term value(1) Balance, December 31, 2021 2,879,246 $ 0.49 Expired (975,161 ) 0.36 Balance, December 31, 2022 1,904,085 $ 0.56 Expired (340,000 ) 0.30 Balance, December 31, 2023 1,564,085 $ 0.61 1.1 $ — ( 1 December 31, 2023 . Non-Plan Options issued Activity of our non-plan stock options issued for the years ended December 31, 2023 2022 Weighted Weighted Non-plan average average Aggregate options exercise price remaining intrinsic outstanding per share term value(1) Balance, December 31, 2021 20,119,207 $ 0.39 Granted 571,358 $ 0.19 Expired (1,666,736 ) $ 0.31 Balance, December 31, 2022 19,023,829 $ 0.39 Granted 60,040 $ 0.20 Expired (1,708,825 ) $ 0.30 Balance, December 31, 2023 17,375,044 $ 0.39 3.2 Unvested (437,500 ) $ 0.45 Vested and outstanding, December 31, 2023 16,937,544 $ 0.39 3.2 $ 28,000 ( 1 December 31, 2023 . During the year ended December 31, 2023 , December 31, 2023, During the year ended December 31, 2022 ,

Note 6 - Warrants

Note 6 - Warrants	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Warrants [Text Block]	Note 6 . Warrants We have certain warrants outstanding to purchase our common stock, at various prices, as described in the following table: Weighted Weighted average average Aggregate Warrants price per remaining intrinsic outstanding share term value (1) Balance, December 31, 2021 36,765,562 $ 0.27 Granted 27,137,048 $ 0.23 Expired (14,879,152 ) $ 0.24 Balance, December 31, 2022 49,023,458 $ 0.26 Granted 16,459,374 $ 0.26 Expired (13,892,532 ) $ 0.23 Balance, December 31, 2023 51,590,300 $ 0.27 2.16 $ 18,000 ( 1 December 31, 2023 . Warrants issued in Unit Offerings During the year ended December 31, 2023 , 3 six five During the year ended December 31, 2022 , 3 six five Warrant issued in conjunction with amendment to note payable On March 6, 2023, 4, March 1, 2023”) five Fair Value – Interest Expense To determine interest expense related to our outstanding warrants issued in conjunction with debt offerings, the fair value of each award grant is estimated on the date of grant using the Black-Scholes option pricing model and the relative fair values are amortized over the life of the warrant. For the determination of expense of warrants issued for services, extinguishment of debt and settlement management also uses the option-pricing model. The principal assumptions we used in applying this model were as follows: 2023 2022 Risk free interest rate 3.38 – 4.45 % 3.69 – 3.88 % Expected volatility 49 % 40 % Expected dividend yield — — Forfeiture rate — — Expected life in years .5 – 5 3 The risk-free interest rate is based on U.S. Treasury yields in effect at the time of grant. Expected volatilities are based on historical volatility of our common stock. The expected life in years is based on the contract term of the warrant.

Note 7 - Accounts Payable and A

Note 7 - Accounts Payable and Accrued Expenses	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 7 . Accounts Payable and Accrued Expenses As of December 31, 2023 , Intercompany Category BioLargo ONM BLEST Canada BETI amounts Totals Accounts payable $ 163 $ 964 $ 34 $ 93 $ 40 $ (82 ) $ 1,212 Accrued payroll 49 86 116 — — 251 Accrued interest 25 — — — — 25 Total $ 1,488 As of December 31, 2022 , Intercompany Category BioLargo ONM BLEST Canada amounts Totals Accounts payable $ 187 $ 486 $ 7 $ 119 $ (82 ) $ 717 Accrued payroll 20 58 120 — — 198 Accrued interest 25 — — — — 25 Total $ 940 See Note 10 ,

Note 8 - Provision for Income T

Note 8 - Provision for Income Taxes	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 8 . Provision for Income Taxes Given our historical losses from operations, income tax obligations have been limited to the minimum franchise tax assessed by the State of California. Since 2016 , not 80% . not not A reconciliation of income tax expense (benefit) computed at the statutory federal tax rates to income taxes as reflected in the financial statements is as follows: 2023 2022 Rate Rate Statutory U.S. federal tax rate (21.0 %) (21.0 %) Permanent differences: State and local income taxes, net of federal benefit 0.0 % 0.0 % Stock compensation 10.0 % 11.0 % Other 1.4 % 1.0 % Valuation Allowance 9.6 % 9.0 % Total 0.0 % 0.0 % Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company’s deferred tax assets and liabilities as of December 31, 2023 2022 2023 2022 Net operating loss carryforwards $ 22,255,079 $ 21,314,069 Valuation allowance (22,255,079 ) (21,314,069 ) Total net deferred tax assets $ — $ — The Company has evaluated the positive and negative evidence bearing upon its ability to realize its deferred tax assets, which are comprised primarily of net operating loss carryforwards. Management has considered the Company’s history of cumulative net losses in the United States, estimated future taxable income and prudent and feasible tax planning strategies and has concluded that it is more likely than not not December 31, 2023 2022, At December 31, 2023, 2003 may 382 383 1986, may not may The Company is subject to tax in the United States (“U.S.”) and files income tax returns in the U.S. Federal jurisdiction and several states and local jurisdictions where the Company has determined it has tax nexus. The Company is subject to U.S. Federal, state and local income tax examinations by tax authorities for periods after 2019. not

Note 9 - BioLargo Energy Techno

Note 9 - BioLargo Energy Technologies, Inc.	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Noncontrolling Interest Disclosure [Text Block]	Note 10 . Noncontrolling Interest Clyra Medical As discussed in Note 2 December 31, 2023 On December 15, 2023, one 1 Impairment of Other Asset, Prepaid Marketing On December 30, 2015 , four June 30, 2020 , three not , During 2023, not December 31, 2023 , During 2022, Debt Obligations of Clyra Medical Promissory Note On April 8, 2022 , April 8, 2024 , may Line of Credit On June 30, 2020 , one 15%, one first 180 may On December 13, 2022 , September 30, 2024 , 30 January 2023. As of December 31, 2023 , December 31, 2022 , $161,000. Equity Transactions As of December 31, 2023 , Sales of Common Stock During the year ended December 31, 2023 , February 28, 2027, one On March 2, 2022 , Sales of Series A Preferred Stock During the year ended December 31, 2023, 35 3 no one may may 20% 30 may January 1, 2025, June 30, 2026. On December 20, 2022 , two 3 one may may 20% 30 may January 1, 2025, June 30, 2026. On July 20, 2023, December 31, 2022, Stock Options Weighted Weighted Clyra average average options exercise price remaining outstanding per share term Balance, December 31, 2021 1,400,421 $ 0.01 Granted 182,908 $ 0.40 Balance, December 31, 2022 1,583,329 $ 0.06 Granted 191,981 $ 0.01 Exercised (296,389 ) $ 1.97 Balance, December 31, 2023 1,478,921 $ 0.31 7.0 Unvested (21,525 ) $ 2.71 Balance, December 31, 2023 1,457,396 $ 0.28 7.0 Clyra issues options to its employees and consultants in lieu of compensation owed on a regular basis. During the years ended December 31, 2023 2022 , December 31, 2023 , $0.01 December 31, 2022, $0.01 December 31, 2023, 2022 no December 31, 2023, December 31, 2022, , Accounts Payable and Accrued Expenses At December 31, 2023 2022 , Category December 31, 2023 December 31, 2022 Accounts payable $ 135 $ 186 Accrued payroll 7 45 Accrued dividend 242 — Accrued interest 13 7 Total $ 397 $ 238
BioLargo Energy Technologies, Inc (BETI) [Member]
Notes to Financial Statements
Noncontrolling Interest Disclosure [Text Block]	Note 9. BioLargo Energy Technologies, Inc. (BETI) BioLargo Energy Technologies, Inc. (“BETI”) was formed for the purpose of commercializing a liquid sodium battery technology. BioLargo purchased 9,000,000 shares of BETI common stock upon its formation, and was initially its sole stockholder. During the year ended December 31, 2023, 4 may 20 2024. As of December 31, 2023,

Note 10 - Noncontrolling Intere

Note 10 - Noncontrolling Interest - Clyra Medical	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Noncontrolling Interest Disclosure [Text Block]	Note 10 . Noncontrolling Interest Clyra Medical As discussed in Note 2 December 31, 2023 On December 15, 2023, one 1 Impairment of Other Asset, Prepaid Marketing On December 30, 2015 , four June 30, 2020 , three not , During 2023, not December 31, 2023 , During 2022, Debt Obligations of Clyra Medical Promissory Note On April 8, 2022 , April 8, 2024 , may Line of Credit On June 30, 2020 , one 15%, one first 180 may On December 13, 2022 , September 30, 2024 , 30 January 2023. As of December 31, 2023 , December 31, 2022 , $161,000. Equity Transactions As of December 31, 2023 , Sales of Common Stock During the year ended December 31, 2023 , February 28, 2027, one On March 2, 2022 , Sales of Series A Preferred Stock During the year ended December 31, 2023, 35 3 no one may may 20% 30 may January 1, 2025, June 30, 2026. On December 20, 2022 , two 3 one may may 20% 30 may January 1, 2025, June 30, 2026. On July 20, 2023, December 31, 2022, Stock Options Weighted Weighted Clyra average average options exercise price remaining outstanding per share term Balance, December 31, 2021 1,400,421 $ 0.01 Granted 182,908 $ 0.40 Balance, December 31, 2022 1,583,329 $ 0.06 Granted 191,981 $ 0.01 Exercised (296,389 ) $ 1.97 Balance, December 31, 2023 1,478,921 $ 0.31 7.0 Unvested (21,525 ) $ 2.71 Balance, December 31, 2023 1,457,396 $ 0.28 7.0 Clyra issues options to its employees and consultants in lieu of compensation owed on a regular basis. During the years ended December 31, 2023 2022 , December 31, 2023 , $0.01 December 31, 2022, $0.01 December 31, 2023, 2022 no December 31, 2023, December 31, 2022, , Accounts Payable and Accrued Expenses At December 31, 2023 2022 , Category December 31, 2023 December 31, 2022 Accounts payable $ 135 $ 186 Accrued payroll 7 45 Accrued dividend 242 — Accrued interest 13 7 Total $ 397 $ 238

Note 11 - BioLargo Engineering,

Note 11 - BioLargo Engineering, Science and Technologies, LLC	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Wholly-Owned Subsidiary [Text Block]	Note 11 . BioLargo Engineering, Science and Technologies, LLC In September 2017 , three six 12 two no five five March 31, 2018 ( not first September 2018 . The BLEST Compensation Committee has met regularly since the subsidiary commenced operations. In 2018 , not not December 2022 , December 2023 , one one December 31, 2023, 2022, $135,000 .

Note 12 - Business Segment Info

Note 12 - Business Segment Information	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	Note 12 . Business Segment Information For the years ended December 31, 2023 2022, five four 1. ONM Environmental -- which sells odor and volatile organic control products and services, located in Westminster, California; 2. BLEST - which provides professional engineering services on a time and materials basis for outside clients and supports our internal operations as needed., located in Oak Ridge, Tennessee; 3. Clyra Medical Technologies (“Clyra Medical”) -- which develops and sells medical products based on our technologies; 4. BioLargo Energy Technologies, Inc. ("BETI") - which is developing our proprietary battery technology; and 5. BioLargo Canada (formerly named BioLargo Water) -- the main hub of our scientists researching and developing our technologies, located in Edmonton, Alberta Canada. Other than ONM Environmental, none third The Chief Operating Decision Makers for the segments are: Joseph Provenzano, President of ONM, Randall Moore, President of BLEST, Steven Harrison, President of Clyra Medical, Dennis Calvert, President of BETI, and Richard Smith, President of BioLargo Canada. The segment information for the years December 31, 2023 2022 , 2023 2022 Revenues BioLargo corporate $ — $ 5 ONM Environmental 11,440 4,374 BLEST 2,397 1,943 Clyra Medical 20 56 BioLargo Canada 30 1 Intersegment revenue (1,657 ) (495 ) Total $ 12,230 $ 5,884 Research and development BioLargo corporate $ (764 ) $ (674 ) ONM Environmental (15 ) — BLEST (1,256 ) (469 ) Clyra Medical (335 ) (110 ) BETI (1,043 ) — BioLargo Canada (526 ) (565 ) Intersegment research and development 1,657 499 Total $ (2,282 ) $ (1,319 ) Depreciation expense BioLargo corporate $ 34 $ 3 ONM Environmental 21 3 BLEST 9 9 Clyra Medical 39 30 Total $ 103 $ 45 Stock option expense $ 1,864 $ 1,663 BioLargo corporate 260 408 Clyra Medical $ 2,124 $ 2,071 Total Operating income (loss) BioLargo corporate $ (3,320 ) $ (3,971 ) ONM Environmental 4,335 1,130 BLEST (1,619 ) (452 ) Clyra Medical (2,102 ) (1,383 ) BETI (1,179 ) — BioLargo Canada (695 ) (714 ) Total $ (4,580 ) $ (5,390 ) Interest expense BioLargo corporate $ (49 ) $ (24 ) ONM Environmental $ (6 ) — Clyra Medical (36 ) (29 ) Total $ (91 ) $ (53 ) Net income (loss) BioLargo corporate $ (3,369 ) $ (3,995 ) ONM Environmental 4,329 1,304 BLEST (1,619 ) (425 ) Clyra Medical (2,097 ) (1,412 ) BETI (1,179 ) — BioLargo Canada (713 ) (604 ) Consolidated net loss $ (4,648 ) $ (5,132 ) As of December 31, 2023 BioLargo ONM Clyra BLEST BETI Canada Elimination Total Tangible assets $ 942 $ 4,624 $ 432 $ 1,083 4 $ 50 $ (41 ) $ 7,094 Right of use 394 — — 698 — — — 1,092 Investment in South Korean joint venture 19 — — — — — — 19 Total $ 1,355 $ 4,624 $ 432 $ 1,781 $ 4 $ 50 $ (41 ) $ 8,205 As of December 31, 2022 BioLargo ONM Clyra BLEST BETI Canada Elimination Total Tangible assets $ 669 $ 2,064 $ 631 $ 441 — $ 194 $ (41 ) $ 3,958 Right of use 136 — — 731 — — — 867 Investment in South Korean joint venture 33 — — — — — — 33 Total $ 838 $ 2,064 $ 631 $ 1,172 $ — $ 194 $ (41 ) $ 4,858

Note 13 - Commitments and Conti

Note 13 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 13 . Leases We have long-term operating leases for office, industrial and laboratory space in Westminster, California, Oak Ridge, Tennessee, and Alberta, Canada. Payments made under operating leases are charged to the Consolidated Statement of Operations and Comprehensive Loss on a straight-line basis over the term of the operating lease agreement. Short-term leases less than one not December 31, 2023 2022 , August 2024 . four four December 31, 2023. September 2022 , ten ten December 31, 2022. one None no not no December 31, 2023, seven As of December 31, 2023 , seven five BioLargo Year ending Corp / ONM BLEST Total December 31, 2024 122,000 154,000 276,000 December 31, 2025 125,000 157,000 282,000 December 31, 2026 129,000 160,000 289,000 December 31, 2027 133,000 163,000 296,000 December 31, 2028 79,000 166,000 245,000 Thereafter — 654,000 654,000 Total minimum lease payments $ 588,000 $ 1,454,000 $ 2,042,000 Less imputed interest (933,000 ) Total operating lease liability $ 1,109,000

Note 14 - Subsequent Events

Note 14 - Subsequent Events	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Subsequent Events [Text Block]	Note 14 . Subsequent Events. Management has evaluated subsequent events through the date of the filing of this Annual Report and management noted the following for disclosure. Sales of Common Stock From January 1, 2024, March 29, 2024, 2022 3 1 333 268973 3. From January 1, 2024, March 29, 2024, five six five 3 6 10% 10% Warrants From January 1, 2024, March 29, 2024, Clyra Medical From January 1, 2024, March 29, 2024, February 28, 2027, four

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The consolidated financial statements include the accounts of the Company, its wholly-owned subsidiaries, and partially-owned subsidiaries. All intercompany accounts and transactions have been eliminated.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency The Company has designated the functional currency of BioLargo Canada to be the Canadian dollar. Therefore, translation gains and losses resulting from differences in exchange rates are recorded in accumulated other comprehensive loss.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three one $250,000 not As of December 31, 2023 2022 December 31, 2023 December 31, 2022 BioLargo, Inc. and subsidiaries $ 3,142 $ 1,685 Clyra Medical Technologies, Inc. 397 166 Total $ 3,539 $ 1,851
Receivable [Policy Text Block]	Accounts Receivable In June 2016, 2016 13, January 1, 2023 Accounts receivable are customer obligations that are unconditional. Accounts receivable are presented net of an allowance for doubtful accounts for expected credit losses, which represents an estimate of amounts that may not no not December 31, 2023, December 31, 2022, December 31, 2023,
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Credit Concentration We have a limited number of customers that account for significant portions of our revenue. During the year ended December 31, 2023 one December 31, 2022 two December 31, 2023 December 31, 2022 Customer A 82 % 47 % Customer B <10 % 10 % We had one December 31, 2023 2022 , December 31, 2023 December 31, 2022 Customer A 68 % 24 %
Inventory, Policy [Policy Text Block]	Inventory Inventories are stated at the lower of cost or net realizable value using the average cost method. The allowance for obsolete inventory as of December 31, 2023 2022 December 31, 2023 December 31, 2022 Raw material $ 79 $ 46 Finished goods 74 74 Total $ 153 $ 120
Other Assets, Policy [Policy Text Block]	Other Non-Current Assets Other non-current assets consisted of (i) security deposits related to our business offices, (ii) three October 22, 2021 , 2022 2022 2023, 2023, not not December 31, 2023 December 31, 2022 Patents $ 34 $ 34 Security deposits 36 36 Tax credit receivable — 54 Total $ 70 $ 124
Equity Method Investments [Policy Text Block]	Equity Method of Accounting On March 20, 2020 , We account for our investment in the joint venture under the equity method of accounting. We have determined that while we have significant influence over the joint venture through our technology license and our position on the Board of Directors, we do not December 31, 2023 2022 ,
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment Long-lived and definite lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not For the year ended December 31, 2023 , 10 December 31, 2023 2022
Earnings Per Share, Policy [Policy Text Block]	Loss Per Share We report basic and diluted loss per share (“LPS”) for common and common share equivalents. Basic LPS is computed by dividing reported earnings by the weighted average shares outstanding. Diluted LPS is computed by adding to the weighted average shares the dilutive effect if convertible notes payable, stock options and warrants were exercised into common stock. For the years ended December 31, 2023 2022 ,
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and revenues and expenses during the year reported. Actual results could differ from those estimates. Estimates are used when accounting for stock-based transactions, debt transactions, derivative liabilities, allowance for bad debt, asset depreciation and amortization, impairment expense, among others. The methods, estimates and judgments we use in applying these most critical accounting policies have a significant impact on the results of our consolidated financial statements.
Share-Based Payment Arrangement [Policy Text Block]	Share-Based Compensation Expense We recognize compensation expense for stock option awards on a straight-line basis over the applicable service period of the award, which is the vesting period. Fair value is determined on the grant date. Share-based compensation expense is based on the grant date fair value estimated using the Black-Scholes Option Pricing Model. For stock and stock options issued to consultants and other non-employees for services, the Company measures and records an expense as of the earlier of the date at which either: a commitment for performance by the non-employee has been reached or the non-employee’s performance is complete. The equity instruments are measured at the current fair value, and for stock options, the instruments are measured at fair value using the Black Scholes option model. The following methodology and assumptions were used to calculate share-based compensation for the years ended December 31, 2023 2022 : 2023 2022 Non Plan 2018 Plan Non Plan 2018 Plan Risk free interest rate 3.48 - 3.58 % 3.48 - 4.45 % 2.32 - 3.83 % 2.32 - 3.83 % Expected volatility 114 % 102 - 114 % 114 - 117 % 114 - 117 % Expected dividend yield — — — — Forfeiture rate — — — — Life in years 10 10 10 10 Expected price volatility is the measure by which our stock price is expected to fluctuate during the expected term of an option. Expected volatility is derived from the historical daily change in the market price of our common stock, as we believe that historical volatility is the best indicator of future volatility. The risk-free interest rate used in the Black-Scholes calculation is based on the prevailing U.S. Treasury yield as determined by the U.S. Federal Reserve. We have never paid any cash dividends on our common stock and do not
Warrant Policy [Policy Text Block]	Warrants Warrants issued with our convertible and non-convertible debt instruments are accounted for under the fair value and relative fair value method. The warrant is first not . not If the warrant is determined to not Convertible debt instruments are recorded at fair value, limited to a relative fair value based upon the percentage of its fair value to the total fair value including the fair value of the warrant. The warrant relative fair values are also recorded as a discount to the convertible promissory notes. As present, these equity features of the convertible promissory notes have recorded a discount to the convertible notes that is substantially equal to the proceeds received.
Non Cash Transactions [Policy Text Block]	Non-Cash Transactions We have established a policy relative to the methodology to determine the value assigned to each intangible we acquire, and/or services or products received for non-cash consideration of our common stock. The value is based on the market price of our common stock issued as consideration, at the date of the agreement of each transaction or when the service is rendered or product is received.
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition We account for revenue in accordance with ASC 606 , Step 1: Step 2: Step 3: Step 4: Step 5: The Company’s products are sold through a contract with the customer and a written purchase order, in which the details of the contract are defined including the transaction price and method of shipment. The only performance obligation is to create and ship the product, and each product has separate pricing. Revenue is recognized at a point in time when the goods are shipped if the agreement is FOB manufacturer, and when goods are delivered if FOB destination. Revenue is recognized with a reduction for sales discounts, as appropriate and negotiated in the customer’s purchase order. Service contracts are performed through a written contract, which specifies the performance obligations and the rate at which the services will be billed, typically by time and materials. Each service is separately negotiated and priced. Revenue is recognized as services are performed and completed, or, for services related to product installations, at the completion of the installation. A few contracts have called for milestone or fixed cost payments, where we invoice an agreed-to amount per month for the life of the contract. In these instances, completed work, billed hourly, is recognized as revenue. If the billing amount is greater or lesser than the completed work, a receivable or payable is created. These accounts are adjusted upon additional billings as the work is completed. To date, there have been no The Company has outstanding contract liability obligations of $303,000 and $17,000 as of December 31, 2023, 2022, December 31, 2023, 2022, $113,000 December 31, 2023, 2022, $71,000, not As we generate revenues from royalties or license fees from our intellectual property, a licensee will pay a license fee in one third
Government Grants [Policy Text Block]	Government Grants We have been awarded multiple research grants from the private and public Canadian research programs. Income we receive directly from grants is recorded as other income. We have been awarded over 80 first 2 015 . third third six eighteen not The grants typically provide for (i) recurring monthly amounts, (ii) reimbursement of costs for research talent for which we invoice to request payment, and (iii) ancillary cost reimbursement for research talent travel related costs. All awarded grants have specific requirements on how the money is spent, typically to employ researchers. None may Not no
Income Tax, Policy [Policy Text Block]	Income Taxes The asset and liability approach is used to recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of asset and liabilities. Deferred tax assets and liabilities are determined based on the differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect on deferred tax asset and liabilities of a change in tax rates is recognized in operations in the year that includes the enactment date. We account for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. Under GAAP, the tax effects of a position are recognized only if it is “more-likely-than- not” not not” no December 31, 2023 2022 . The Company assessed its earnings history, trends and estimates of future earnings and determined that the deferred tax asset could not December 31, 2023 . The Company recognizes interest and penalties on income taxes as a component of income tax expense, should such an expense be realized.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments Management believes the carrying amounts of the Company’s financial instruments as of December 31, 2023 2022
Tax Credits [Policy Text Block]	Tax Credits Our research and development activities in Canada may not not
Lessee, Leases [Policy Text Block]	Leases At inception of a lease contract, we assess whether the contract is, or contains, a lease. Our assessment is based on: ( 1 2 3 not no not not 12 not December 31, 2023 2022, December 31, 2023 2022,
Property, Plant and Equipment, Policy [Policy Text Block]	Equipment Equipment and leasehold improvements is stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range from 3 - 10 years. Additions, renewals, and betterments that significantly extend the life of the asset are capitalized. Expenditures for repairs and maintenance are charged to expense as incurred. For assets sold or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the accounts, and any related gain or loss is reflected in income for the period.
Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]	Noncontrolling Interest A noncontrolling interest is defined as the portion of the equity in an entity not not 810 10 20, three December 31, 2023 2022. December 31, 2023, 2022, December 31, 2023. 2023.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In November 2023, 2023 07, 280 1. Require that a public entity disclose, on an annual and interim basis, significant segment expenses that are regularly provided to the chief operating decision maker (CODM) and included within each reported measure of segment profit or loss (collectively referred to as the “significant expense principle”). 2. Require that a public entity disclose, on an annual and interim basis, an amount for other segment items by reportable segment and a description of its composition. The other segment items category is the difference between segment revenue less the segment expenses disclosed under the significant expense principle and each reported measure of segment profit or loss. 3. Require that a public entity provide all annual disclosures about a reportable segment’s profit or loss and assets currently required by Topic 280 4. Clarify that if the CODM uses more than one may one 5. Require that a public entity disclose the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. 6. Require that a public entity that has a single reportable segment provide all the disclosures required by the amendments in this Update and all existing segment disclosures in Topic 280. This Update is effective for fiscal years beginning after December 15, 2023, December 15, 2024. December 31, 2023 no 12

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Cash and Cash Equivalents [Table Text Block]	December 31, 2023 December 31, 2022 BioLargo, Inc. and subsidiaries $ 3,142 $ 1,685 Clyra Medical Technologies, Inc. 397 166 Total $ 3,539 $ 1,851
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	December 31, 2023 December 31, 2022 Customer A 82 % 47 % Customer B <10 % 10 % December 31, 2023 December 31, 2022 Customer A 68 % 24 %
Schedule of Inventory, Current [Table Text Block]	December 31, 2023 December 31, 2022 Raw material $ 79 $ 46 Finished goods 74 74 Total $ 153 $ 120
Schedule of Other Assets, Noncurrent [Table Text Block]	December 31, 2023 December 31, 2022 Patents $ 34 $ 34 Security deposits 36 36 Tax credit receivable — 54 Total $ 70 $ 124
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2023 2022 Non Plan 2018 Plan Non Plan 2018 Plan Risk free interest rate 3.48 - 3.58 % 3.48 - 4.45 % 2.32 - 3.83 % 2.32 - 3.83 % Expected volatility 114 % 102 - 114 % 114 - 117 % 114 - 117 % Expected dividend yield — — — — Forfeiture rate — — — — Life in years 10 10 10 10

Note 4 - Debt Obligations (Tabl

Note 4 - Debt Obligations (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Debt [Table Text Block]	December 31, 2023 2022 Current portion of debt: SBA Paycheck Protection Program loan $ 43 $ 43 Vehicle loan, current portion 13 — Convertible note payable, matures March 1, 2023 — 50 SBA EIDL Loan, matures July 2053, current portion 10 10 Debt discount, net of amortization — (3 ) Total current portion of debt $ 66 $ 100 Long-term debt: SBA Paycheck Protection Program loans, matures May 2025 $ 97 $ 97 Vehicle loan, matures March 2029 55 — SBA EIDL Loan, matures July 2053 137 140 Total long-term debt, net of current $ 289 $ 237 Total $ 355 $ 337

Note 5 - Share-based Compensa_2

Note 5 - Share-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Weighted Weighted average average Aggregate Options exercise price per remaining intrinsic outstanding share Term value(1) Balance, December 31, 2021 23,186,142 $ 0.19 Granted 6,322,233 $ 0.22 Exercised (290,243 ) $ 0.16 Expired (733,583 ) $ 0.33 Balance, December 31, 2022 28,484,549 $ 0.19 Granted 12,623,899 $ 0.17 Balance, December 31, 2023 41,108,448 $ 0.19 7.7 Non-vested (5,067,958 ) $ 0.18 Vested, December 31, 2023 36,040,490 $ 0.19 7.7 $ 287,000 Weighted Weighted average average Aggregate Options exercise price remaining intrinsic outstanding per share term value(1) Balance, December 31, 2021 2,879,246 $ 0.49 Expired (975,161 ) 0.36 Balance, December 31, 2022 1,904,085 $ 0.56 Expired (340,000 ) 0.30 Balance, December 31, 2023 1,564,085 $ 0.61 1.1 $ — Weighted Weighted Non-plan average average Aggregate options exercise price remaining intrinsic outstanding per share term value(1) Balance, December 31, 2021 20,119,207 $ 0.39 Granted 571,358 $ 0.19 Expired (1,666,736 ) $ 0.31 Balance, December 31, 2022 19,023,829 $ 0.39 Granted 60,040 $ 0.20 Expired (1,708,825 ) $ 0.30 Balance, December 31, 2023 17,375,044 $ 0.39 3.2 Unvested (437,500 ) $ 0.45 Vested and outstanding, December 31, 2023 16,937,544 $ 0.39 3.2 $ 28,000

Note 6 - Warrants (Tables)

Note 6 - Warrants (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Weighted Weighted average average Aggregate Warrants price per remaining intrinsic outstanding share term value (1) Balance, December 31, 2021 36,765,562 $ 0.27 Granted 27,137,048 $ 0.23 Expired (14,879,152 ) $ 0.24 Balance, December 31, 2022 49,023,458 $ 0.26 Granted 16,459,374 $ 0.26 Expired (13,892,532 ) $ 0.23 Balance, December 31, 2023 51,590,300 $ 0.27 2.16 $ 18,000
Schedule Of Assumptions Used To Determine Fair Value Of Warrants [Table Text Block]	2023 2022 Risk free interest rate 3.38 – 4.45 % 3.69 – 3.88 % Expected volatility 49 % 40 % Expected dividend yield — — Forfeiture rate — — Expected life in years .5 – 5 3

Note 7 - Accounts Payable and_2

Note 7 - Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	Intercompany Category BioLargo ONM BLEST Canada BETI amounts Totals Accounts payable $ 163 $ 964 $ 34 $ 93 $ 40 $ (82 ) $ 1,212 Accrued payroll 49 86 116 — — 251 Accrued interest 25 — — — — 25 Total $ 1,488 Intercompany Category BioLargo ONM BLEST Canada amounts Totals Accounts payable $ 187 $ 486 $ 7 $ 119 $ (82 ) $ 717 Accrued payroll 20 58 120 — — 198 Accrued interest 25 — — — — 25 Total $ 940

Note 8 - Provision for Income_2

Note 8 - Provision for Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2023 2022 Rate Rate Statutory U.S. federal tax rate (21.0 %) (21.0 %) Permanent differences: State and local income taxes, net of federal benefit 0.0 % 0.0 % Stock compensation 10.0 % 11.0 % Other 1.4 % 1.0 % Valuation Allowance 9.6 % 9.0 % Total 0.0 % 0.0 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	2023 2022 Net operating loss carryforwards $ 22,255,079 $ 21,314,069 Valuation allowance (22,255,079 ) (21,314,069 ) Total net deferred tax assets $ — $ —

Note 10 - Noncontrolling Inte_2

Note 10 - Noncontrolling Interest - Clyra Medical (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Other Ownership Interests [Table Text Block]	Weighted Weighted Clyra average average options exercise price remaining outstanding per share term Balance, December 31, 2021 1,400,421 $ 0.01 Granted 182,908 $ 0.40 Balance, December 31, 2022 1,583,329 $ 0.06 Granted 191,981 $ 0.01 Exercised (296,389 ) $ 1.97 Balance, December 31, 2023 1,478,921 $ 0.31 7.0 Unvested (21,525 ) $ 2.71 Balance, December 31, 2023 1,457,396 $ 0.28 7.0
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	Intercompany Category BioLargo ONM BLEST Canada BETI amounts Totals Accounts payable $ 163 $ 964 $ 34 $ 93 $ 40 $ (82 ) $ 1,212 Accrued payroll 49 86 116 — — 251 Accrued interest 25 — — — — 25 Total $ 1,488 Intercompany Category BioLargo ONM BLEST Canada amounts Totals Accounts payable $ 187 $ 486 $ 7 $ 119 $ (82 ) $ 717 Accrued payroll 20 58 120 — — 198 Accrued interest 25 — — — — 25 Total $ 940
Clyra Medical [Member]
Notes Tables
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	Category December 31, 2023 December 31, 2022 Accounts payable $ 135 $ 186 Accrued payroll 7 45 Accrued dividend 242 — Accrued interest 13 7 Total $ 397 $ 238

Note 12 - Business Segment In_2

Note 12 - Business Segment Information (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	2023 2022 Revenues BioLargo corporate $ — $ 5 ONM Environmental 11,440 4,374 BLEST 2,397 1,943 Clyra Medical 20 56 BioLargo Canada 30 1 Intersegment revenue (1,657 ) (495 ) Total $ 12,230 $ 5,884 Research and development BioLargo corporate $ (764 ) $ (674 ) ONM Environmental (15 ) — BLEST (1,256 ) (469 ) Clyra Medical (335 ) (110 ) BETI (1,043 ) — BioLargo Canada (526 ) (565 ) Intersegment research and development 1,657 499 Total $ (2,282 ) $ (1,319 ) Depreciation expense BioLargo corporate $ 34 $ 3 ONM Environmental 21 3 BLEST 9 9 Clyra Medical 39 30 Total $ 103 $ 45 Stock option expense $ 1,864 $ 1,663 BioLargo corporate 260 408 Clyra Medical $ 2,124 $ 2,071 Total Operating income (loss) BioLargo corporate $ (3,320 ) $ (3,971 ) ONM Environmental 4,335 1,130 BLEST (1,619 ) (452 ) Clyra Medical (2,102 ) (1,383 ) BETI (1,179 ) — BioLargo Canada (695 ) (714 ) Total $ (4,580 ) $ (5,390 ) Interest expense BioLargo corporate $ (49 ) $ (24 ) ONM Environmental $ (6 ) — Clyra Medical (36 ) (29 ) Total $ (91 ) $ (53 ) Net income (loss) BioLargo corporate $ (3,369 ) $ (3,995 ) ONM Environmental 4,329 1,304 BLEST (1,619 ) (425 ) Clyra Medical (2,097 ) (1,412 ) BETI (1,179 ) — BioLargo Canada (713 ) (604 ) Consolidated net loss $ (4,648 ) $ (5,132 ) As of December 31, 2023 BioLargo ONM Clyra BLEST BETI Canada Elimination Total Tangible assets $ 942 $ 4,624 $ 432 $ 1,083 4 $ 50 $ (41 ) $ 7,094 Right of use 394 — — 698 — — — 1,092 Investment in South Korean joint venture 19 — — — — — — 19 Total $ 1,355 $ 4,624 $ 432 $ 1,781 $ 4 $ 50 $ (41 ) $ 8,205 As of December 31, 2022 BioLargo ONM Clyra BLEST BETI Canada Elimination Total Tangible assets $ 669 $ 2,064 $ 631 $ 441 — $ 194 $ (41 ) $ 3,958 Right of use 136 — — 731 — — — 867 Investment in South Korean joint venture 33 — — — — — — 33 Total $ 838 $ 2,064 $ 631 $ 1,172 $ — $ 194 $ (41 ) $ 4,858

Note 13 - Commitments and Con_2

Note 13 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]	BioLargo Year ending Corp / ONM BLEST Total December 31, 2024 122,000 154,000 276,000 December 31, 2025 125,000 157,000 282,000 December 31, 2026 129,000 160,000 289,000 December 31, 2027 133,000 163,000 296,000 December 31, 2028 79,000 166,000 245,000 Thereafter — 654,000 654,000 Total minimum lease payments $ 588,000 $ 1,454,000 $ 2,042,000 Less imputed interest (933,000 ) Total operating lease liability $ 1,109,000

Note 1 - Business and Organiz_2

Note 1 - Business and Organization (Details Textual)	12 Months Ended
	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Sep. 30, 2017
Revenues	$ 12,230,000
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	(4,648,000)	$ (5,132,000)
Net Cash Provided by (Used in) Operating Activities	(2,365,000)	(2,762,000)
Working Capital (Deficit)	3,652,000
Assets, Current	6,362,000	3,153,000
Stock Issued During Period, Value, New Issues	2,153,000	3,617,000
Proceeds from Issuance of Preferred Stock and Preference Stock	$ 1,575,000	$ 225,000
Number of Wholly-Owned Subsidiaries	5
BioLargo Energy Technologies, Inc (BETI) [Member]
Subsidiary, Ownership Percentage, Parent	96%
Clyra Medical Technologies [Member]
Subsidiary, Ownership Percentage, Parent	53%
BioLargo Engineering, Science & Technologies, LLC [Member]
Subsidiary, Ownership Percentage, Parent	82%		100%
Clyra Medical Common Stock [Member]
Proceeds from Issuance or Sale of Equity	$ 35,000
BETI Common Stock [Member]
Proceeds from Issuance or Sale of Equity	1,005,000
BETI Common Stock [Member] | Conversion Debt to Equity [Member]
Debt Conversion, Converted Instrument, Amount	50,000
Lincoln Park Capital Fund, LLC [Member]
Stock Issued During Period, Value, New Issues	995,000
The 2020 Unit Offering [Member]
Stock Issued During Period, Value, New Issues	1,158,000
Biolargo [Member] | BETI Common Stock [Member]
Proceeds from Issuance or Sale of Equity	$ 100,000

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual)			12 Months Ended
	Oct. 22, 2021 USD ($) $ / shares shares	Mar. 20, 2020 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Accounts Receivable, Allowance for Credit Loss, Current			$ 84,000	$ 12,000
Accounts Receivable, Allowance for Credit Loss, Writeoff			85,000
Inventory Valuation Reserves			212,000	158,000
Income (Loss) from Equity Method Investments			(14,000)	(15,000)
Impairment, Long-Lived Asset, Held-for-Use			394,000	197,000
Contract with Customer, Liability			303,000	17,000
Customer Deposit Liability, Current			117,000	184,000
Unrecognized Tax Benefits			$ 0	0
Operating Lease, Weighted Average Discount Rate, Percent			18%
Operating Lease, Right-of-Use Asset			$ 1,092,000	867,000
Operating Lease, Liability			$ 1,109,000	870,000
Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)			3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)			10 years
Canadian Government Grants [Member] | Minimum [Member]
Grant Term (Month)			6 months
Canadian Government Grants [Member] | Maximum [Member]
Grant Term (Month)			18 months
ONM [Member]
Customer Deposit Liability, Current			$ 4,000	71,000
CANADA
Customer Deposit Liability, Current			$ 113,000	$ 113,000
Odin Co Ltd [Member]
Payments to Acquire Interest in Joint Venture		$ 100,000
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage		40%	40%	40%
Income (Loss) from Equity Method Investments			$ (14,000)	$ (15,000)
Odin Co Ltd [Member] | Tomorrow Water [Member]
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage		30%
Odin Co Ltd [Member] | BKT and Tomorrow Water [Member]
Payments to Acquire Interest in Joint Venture		$ 150,000
Clyra Medical Technologies [Member]
Subsidiary, Ownership Percentage, Noncontrolling Owner			47%	47%
BioLargo Engineering, Science & Technologies, LLC [Member]
Subsidiary, Ownership Percentage, Noncontrolling Owner			23%	18%
BioLargo Energy Technologies, Inc (BETI) [Member]
Subsidiary, Ownership Percentage, Noncontrolling Owner			4%
Patents [Member]
Intangible Assets, Net (Excluding Goodwill), Total	$ 34,000
Payments to Acquire Intangible Assets	13,000
Intangible Assets, Remaining Balance After Cash Payment Amount	$ 21,000
Stock Issued During Period, Shares, Issued for Intangible Assets Purchase (in shares) | shares	125,000
Shares Issued, Price Per Share (in dollars per share) | $ / shares	$ 0.17
Customer Concentration Risk [Member] | Revenue from Contract with Customer Benchmark [Member]
Number of Major Customers			1	2
Customer Concentration Risk [Member] | Revenue from Contract with Customer Benchmark [Member] | One Customer [Member]
Concentration Risk, Percentage			10%
Customer Concentration Risk [Member] | Revenue from Contract with Customer Benchmark [Member] | Two Customers [Member]
Concentration Risk, Percentage				10%
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Number of Major Customers			1	1
Customer Concentration Risk [Member] | Accounts Receivable [Member] | One Customer [Member]
Concentration Risk, Percentage			10%	10%

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Summary of Cash Balances (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Cash and Cash Equivalents	$ 3,539	$ 1,851
Parent Company [Member]
Cash and Cash Equivalents	3,142	1,685
Noncontrolling Interest [Member]
Cash and Cash Equivalents	$ 397	$ 166

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Credit Concentration (Details) - Customer Concentration Risk [Member]	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Customer A [Member] | Revenue from Contract with Customer Benchmark [Member]
Credit concentration	82%	47%
Customer A [Member] | Accounts Receivable [Member]
Credit concentration	68%	24%
Customer B [Member] | Revenue from Contract with Customer Benchmark [Member]
Credit concentration	10%	10%

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Raw material	$ 79	$ 46
Finished goods	74	74
Total	$ 153	$ 120

Note 2 - Summary of Significa_7

Note 2 - Summary of Significant Accounting Policies - Other Non-current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Patents	$ 34	$ 34
Security deposits	36	36
Tax credit receivable		54
Total	$ 70	$ 124

Note 2 - Summary of Significa_8

Note 2 - Summary of Significant Accounting Policies - Stock Options, Valuation Assumptions (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Non Plan [Member]
Expected volatility	114%
Expected dividend yield	0%	0%
Forfeiture rate	0%	0%
Life in years (Year)	10 years	10 years
Non Plan [Member] | Minimum [Member]
Risk free interest rate	3.48%	2.32%
Expected volatility		114%
Non Plan [Member] | Maximum [Member]
Risk free interest rate	3.58%	3.83%
Expected volatility		117%
2018 Equity Incentive Plan [Member]
Expected dividend yield	0%	0%
Forfeiture rate	0%	0%
Life in years (Year)	10 years	10 years
2018 Equity Incentive Plan [Member] | Minimum [Member]
Risk free interest rate	3.48%	2.32%
Expected volatility	102%	114%
2018 Equity Incentive Plan [Member] | Maximum [Member]
Risk free interest rate	4.45%	3.83%
Expected volatility	114%	117%

Note 3 - Sale of Stock for Ca_2

Note 3 - Sale of Stock for Cash (Details Textual) - USD ($)	11 Months Ended	12 Months Ended
	Dec. 13, 2022	Dec. 31, 2023	Dec. 31, 2022
Stock Issued During Period, Value, Commitment Fee			$ 0
Proceeds from Issuance of Common Stock		$ 2,153,000	$ 3,617,000
Warrants Issued with 2020 Unit Offering [Member] | Minimum [Member]
Warrants and Rights Outstanding, Term (Month)		6 months
Warrants Issued with 2020 Unit Offering [Member] | Maximum [Member]
Warrants and Rights Outstanding, Term (Month)		5 years
The 2020 Unit Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)		8,170,287	13,568,524
Proceeds from Issuance of Common Stock		$ 1,158,000	$ 2,364,000
Lincoln Park Capital Fund, LLC [Member]
Stock Purchase Agreement, Maximum Amount of Common Stock	$ 10,000,000
Stock Issued During Period, Shares, Commitment Fee (in shares)	1,250,000
Stock Issued During Period, Value, Commitment Fee	$ 240,000
Stock Issued During Period, Shares, New Issues (in shares)		3,833,230	6,011,701
Proceeds from Issuance of Common Stock		$ 995,000	$ 1,253,000

Note 4 - Debt Obligations (Deta

Note 4 - Debt Obligations (Details Textual) - USD ($)			1 Months Ended	12 Months Ended
	Mar. 06, 2023	Feb. 07, 2022	Jul. 31, 2020	Dec. 31, 2023	Dec. 31, 2022	May 12, 2022
Interest Expense, Debt				$ 91,000	$ 53,000
Paycheck Protection Program CARES Act [Member] | ONM [Member]
Extinguishment of Debt, Amount		$ 174,000
Proceeds from Issuance of Debt		$ 217,000
Long-Term Debt				$ 43,000
Paycheck Protection Program CARES Act [Member] | BioLargo Engineering, Science & Technologies, LLC [Member]
Long-Term Debt						$ 97,000
Economic Injury Disaster Loan [Member] | ONM [Member]
Debt Instrument, Face Amount			$ 150,000
Debt Instrument, Interest Rate, Stated Percentage			3.75%
Debt Instrument, Periodic Payment			$ 700
Warrant Issued With Conversion of Note [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	200,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.21
Warrants and Rights Outstanding, Term (Month)	5 years
Conversion of Note into BETI Common Shares [Member]
Debt Conversion, Original Debt, Amount	$ 50,000

Note 4 - Debt Obligations - Sch

Note 4 - Debt Obligations - Schedule of Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Debt discount, net of amortization	$ 0	$ (3)
Total current portion of debt	66	100
Total long-term debt, net of current	289	237
Total	355	337
Vehicle Loan [Member]
Long-term debt, current	13	0
Total long-term debt, net of current	55	0
Paycheck Protection Program CARES Act [Member]
SBA Paycheck Protection Program loan	43	43
SBA Paycheck Protection Program loans, matures May 2025	97	97
Convertible Note, Maturing On March 1, 2023 [Member]
Convertible notes	0	50
Economic Injury Disaster Loan [Member]
Long-term debt, current	10	10
Total long-term debt, net of current	$ 137	$ 140

Note 5 - Share-based Compensa_3

Note 5 - Share-based Compensation (Details Textual) - USD ($)													12 Months Ended
	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Mar. 21, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Mar. 22, 2022	Jun. 22, 2018	Sep. 07, 2017	Dec. 31, 2023	Dec. 31, 2022
Stock Issued During Period, Shares, Issued for Services (in shares)													1,951,541	1,448,512
Stock Issued During Period, Value, Issued for Services													$ 384,000	$ 291,000
Share Price (in dollars per share)	$ 0.17												$ 0.17
2018 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)											10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)	50,000,000										40,000,000		50,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Per Year (in shares)											2,000,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)													12,623,899	6,322,233
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)													$ 0.17	$ 0.22
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 918,000												$ 918,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)													4 years
The 2007 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)												10 years
Non Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)													60,040	571,358
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)													$ 0.2	$ 0.19
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 109,000												$ 109,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)													3 years
Share-Based Payment Arrangement, Option [Member] | Clyra Medical Technologies [Member]
Share-Based Payment Arrangement, Expense													$ 260,000	$ 408,000
Selling, General and Administrative Expenses [Member]
Share-Based Payment Arrangement, Expense													$ 2,124,000	$ 2,071,000
Officer [Member]
Stock Issued During Period, Shares, Issued for Services (in shares)	123,178	69,563	68,541	30,747			268,330	263,895					292,029	532,225
Stock Issued During Period, Value, Issued for Services													$ 48,000	$ 120,000
Shares Issued, Price Per Share (in dollars per share)	$ 0.17	$ 0.17	$ 0.18	$ 0.2			$ 0.27	$ 0.18					$ 0.17
Consultants [Member]
Stock Issued During Period, Shares, Issued for Services (in shares)	261,276	146,123	352,370	899,743		642,041	110,498	76,996	86,752				1,659,512	916,287
Stock Issued During Period, Value, Issued for Services													$ 336,000	$ 171,000
Shares Issued, Price Per Share (in dollars per share)	$ 0.17	$ 0.17	$ 0.18	$ 0.2		$ 0.2	$ 0.27	$ 0.18	$ 0.23				$ 0.17	$ 0.2
Officer, Board of Directors, Employees, and a Consultant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)													12,623,899	6,322,233
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value													$ 2,058,000	$ 1,329,000
CFO and President [Member] | 2018 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)													560,435	495,135
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value													$ 151,000	$ 97,000
CFO and President [Member] | 2018 Equity Incentive Plan [Member] | Minimum [Member]
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)													$ 0.17
CFO and President [Member] | 2018 Equity Incentive Plan [Member] | Maximum [Member]
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)													$ 0.2
Board Of Directors [Member] | 2018 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)													2,213,180	1,861,456
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value													$ 365,000	$ 401,000
Board Of Directors [Member] | 2018 Equity Incentive Plan [Member] | Minimum [Member]
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)													$ 0.17	$ 0.18
Board Of Directors [Member] | 2018 Equity Incentive Plan [Member] | Maximum [Member]
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)													$ 0.2	$ 0.27
Employees [Member] | 2018 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)													4,080,138	2,933,901
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value													$ 658,000	$ 608,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)													4 years	4 years
Employees [Member] | 2018 Equity Incentive Plan [Member] | Minimum [Member]
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)													$ 0.17	$ 0.18
Employees [Member] | 2018 Equity Incentive Plan [Member] | Maximum [Member]
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)													$ 0.2	$ 0.27
Employees and Consultants [Member] | 2018 Equity Incentive Plan [Member]
Stock Issued During Period, Value, Issued for Services													$ 884,000	$ 155,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)													5,470,146	731,741
Chief Financial Officer [Member] | 2018 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)					10 years					10 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)					300,000					300,000			300,000	300,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value													$ 56,000	$ 68,000
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)					$ 0.2					$ 0.24				$ 0.17
Term Extension (Year)					1 year					1 year
Share-based Compensation Arrangement By Share-based Payment Award, Options Grants Per Month, Gross (in shares)					25,000					25,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares (in shares)					25,000					25,000
President [Member] | 2018 Equity Incentive Plan [Member]
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)														$ 0.23
Vendors [Member] | Non Plan [Member]
Share-Based Payment Arrangement, Expense													$ 11,000	$ 109,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)													60,040	571,358
Vendors [Member] | Non Plan [Member] | Minimum [Member]
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)													$ 0.18	$ 0.17
Vendors [Member] | Non Plan [Member] | Maximum [Member]
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)													$ 0.2	$ 0.27

Note 5 - Share-based Compensa_4

Note 5 - Share-based Compensation - Stock Options (Details) - USD ($)		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022
2018 Equity Incentive Plan [Member]
Options outstanding, balance (in shares)		28,484,549	23,186,142
Weighted average exercise price, balance (in dollars per share)		$ 0.19	$ 0.19
Options outstanding, Granted (in shares)		12,623,899	6,322,233
Weighted average exercise price, Granted (in dollars per share)		$ 0.17	$ 0.22
Options outstanding, Exercised (in shares)			(290,243)
Weighted average exercise price, Exercised (in dollars per share)			$ 0.16
Options outstanding, Expired (in shares)			(733,583)
Weighted average exercise price, Expired (in dollars per share)			$ 0.33
Options outstanding, balance (in shares)		41,108,448	28,484,549
Weighted average exercise price, balance (in dollars per share)		$ 0.19	$ 0.19
Weighted average remaining term, balance (Year)		7 years 8 months 12 days
Options outstanding, Non-vested (in shares)		(5,067,958)
Weighted average exercise price, Non-vested (in dollars per share)		$ 0.18
Options outstanding, Vested (in shares)		36,040,490
Weighted average exercise price, Vested (in dollars per share)		$ 0.19
Weighted average remaining term, Vested (Year)		7 years 8 months 12 days
Aggregate intrinsic value, Vested	[1]	$ 287,000
The 2007 Equity Incentive Plan [Member]
Options outstanding, balance (in shares)		1,904,085	2,879,246
Weighted average exercise price, balance (in dollars per share)		$ 0.56	$ 0.49
Options outstanding, Expired (in shares)		(340,000)	(975,161)
Weighted average exercise price, Expired (in dollars per share)		$ 0.3	$ 0.36
Options outstanding, balance (in shares)		1,564,085	1,904,085
Weighted average exercise price, balance (in dollars per share)		$ 0.61	$ 0.56
Weighted average remaining term, balance (Year)		1 year 1 month 6 days
Non Plan [Member]
Options outstanding, balance (in shares)		19,023,829	20,119,207
Weighted average exercise price, balance (in dollars per share)		$ 0.39	$ 0.39
Options outstanding, Granted (in shares)		60,040	571,358
Weighted average exercise price, Granted (in dollars per share)		$ 0.2	$ 0.19
Options outstanding, Expired (in shares)		(1,708,825)	(1,666,736)
Weighted average exercise price, Expired (in dollars per share)		$ 0.3	$ 0.31
Options outstanding, balance (in shares)		17,375,044	19,023,829
Weighted average exercise price, balance (in dollars per share)		$ 0.39	$ 0.39
Weighted average remaining term, balance (Year)		3 years 2 months 12 days
Options outstanding, Non-vested (in shares)		(437,500)
Weighted average exercise price, Non-vested (in dollars per share)		$ 0.45
Options outstanding, Vested (in shares)		16,937,544
Weighted average exercise price, Vested (in dollars per share)		$ 0.39
Weighted average remaining term, Vested (Year)		3 years 2 months 12 days
Aggregate intrinsic value, Vested	[1]	$ 28,000
[1]Aggregate intrinsic value based on closing common stock price of $0.17 at December 31, 2023.

Note 6 - Warrants (Details Text

Note 6 - Warrants (Details Textual) - USD ($)		Dec. 31, 2023	Mar. 06, 2023	Dec. 31, 2022
Share Price (in dollars per share)		$ 0.17
Warrants and Rights Outstanding	[1]	$ 18,000
Note Payable, Maturing March 8, 2023 [Member]
Debt Instrument, Face Amount			$ 50,000
Six-month Warrants in Connection With the 2020 Unit Offering [Member]
Warrants and Rights Outstanding, Term (Month)		6 months		6 months
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)		8,129,687		13,568,524
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.23
Six-month Warrants in Connection With the 2020 Unit Offering [Member] | Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 0.19
Six-month Warrants in Connection With the 2020 Unit Offering [Member] | Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 0.26
Five-year Warrants in Connection With the 2020 Unit Offering [Member]
Warrants and Rights Outstanding, Term (Month)		5 years		5 years
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)		8,129,687		13,568,524
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.29
Five-year Warrants in Connection With the 2020 Unit Offering [Member] | Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 0.24
Five-year Warrants in Connection With the 2020 Unit Offering [Member] | Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 0.33
Warrants Issued in Connection with Conversion of Interest on Note Payable Maturing March 8, 2023 [Member]
Warrants and Rights Outstanding, Term (Month)			5 years
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)			200,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.21
Warrants and Rights Outstanding			$ 30,000
[1]Aggregate intrinsic value based on closing common stock price of $0.17 at December 31, 2023.

Note 6 - Warrants - Warrants Ou

Note 6 - Warrants - Warrants Outstanding (Details) - USD ($)		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022
Warrants outstanding, balance (in shares)		49,023,458	36,765,562
Warrants outstanding, Granted (in shares)		16,459,374	27,137,048
Warrants outstanding, Expired (in shares)		(13,892,532)	(14,879,152)
Warrants outstanding, balance (in shares)		51,590,300	49,023,458
Balance, Weighted Average Remaining Term (Year)		2 years 1 month 28 days
Balance, Aggregate Intrinsic Value	[1]	$ 18,000
Weighted Average [Member]
Weighted average price, balance (in dollars per share)		$ 0.26	$ 0.27
Weighted average price, Granted (in dollars per share)		0.26	0.23
Weighted average price, Expired (in dollars per share)		0.23	0.24
Weighted average price, balance (in dollars per share)		$ 0.27	$ 0.26
[1]Aggregate intrinsic value based on closing common stock price of $0.17 at December 31, 2023.

Note 6 - Warrants - Assumptions

Note 6 - Warrants - Assumptions Used to Determine Fair Value of Warrants (Details)	Dec. 31, 2023	Dec. 31, 2022
Measurement Input, Price Volatility [Member]
Risk free interest rate	0.49	0.40
Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Risk free interest rate	0.0338	0.0369
Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Risk free interest rate	0.0445	0.0388

Note 7 - Accounts Payable and_3

Note 7 - Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Accounts payable	$ 1,212	$ 717
Accrued payroll	251	198
Accrued interest	25	25
Total	1,488	940
Corporate, Non-Segment [Member]
Accounts payable	163	187
Accrued payroll	49	20
Accrued interest	25	25
Operating Segments [Member] | Odor-No-More [Member]
Accounts payable	964	486
Accrued payroll	86	58
Accrued interest	0	0
Operating Segments [Member] | BLEST [Member]
Accounts payable	34	7
Accrued payroll	116	120
Accrued interest	0	0
Operating Segments [Member] | BioLargo Water [Member]
Accounts payable	93	119
Accrued payroll	0	0
Accrued interest	0	0
Operating Segments [Member] | BioLargo Energy Technologies, Inc (BETI) [Member]
Accounts payable	40
Accrued payroll
Accrued interest
Consolidation, Eliminations [Member]
Accounts payable	(82)	(82)
Accrued payroll	0	0
Accrued interest	$ 0	$ 0

Note 8 - Provision for Income_3

Note 8 - Provision for Income Taxes (Details Textual) $ in Millions	Dec. 31, 2023 USD ($)
Domestic Tax Authority [Member]
Operating Loss Carryforwards	$ 95

Note 8 - Provision for Income_4

Note 8 - Provision for Income Taxes - Effective Income Tax Reconciliation (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Statutory U.S. federal tax rate	(21.00%)	(21.00%)
State and local income taxes, net of federal benefit	0%	0%
Stock compensation	10%	11%
Other	1.40%	1%
Valuation Allowance	9.60%	9%
Total	0%	0%

Note 8 - Provision for Income_5

Note 8 - Provision for Income Taxes - Deferred Tax Assets (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Net operating loss carryforwards	$ 22,255,079	$ 21,314,069
Valuation allowance	(22,255,079)	(21,314,069)
Total net deferred tax assets	$ 0

Note 9 - BioLargo Energy Tech_2

Note 9 - BioLargo Energy Technologies, Inc. (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Proceeds from Issuance of Common Stock	$ 2,153,000	$ 3,617,000
BioLargo Energy Technologies, Inc (BETI) [Member]
Investment Owned, Balance, Shares (in shares)	9,050,000
BioLargo Energy Technologies, Inc (BETI) [Member]
Investment Owned, Balance, Shares (in shares)	9,000,000
Stock Issued During Period, Shares, New Issues (in shares)	467,000
Proceeds from Issuance of Common Stock	$ 1,005,000
Stock Conversion, Discount on Volume Weighted average Price	20%
Shares, Outstanding (in shares)	9,467,000
BioLargo Energy Technologies, Inc (BETI) [Member] | Conversion Debt to Equity [Member]
Conversion of Stock, Amount Converted	$ 50,000
BioLargo Energy Technologies, Inc (BETI) [Member] | Biolargo [Member]
Proceeds from Issuance or Sale of Equity	$ 100,000

Note 10 - Noncontrolling Inte_3

Note 10 - Noncontrolling Interest - Clyra Medical (Details Textual)										1 Months Ended	12 Months Ended
		Dec. 25, 2023	Jul. 20, 2023 USD ($) shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 20, 2022 USD ($) $ / shares shares	Mar. 02, 2022 USD ($) shares	Jun. 30, 2020 USD ($) shares	Dec. 31, 2015	Dec. 30, 2015 USD ($)	Jan. 31, 2023 shares	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Apr. 08, 2022 USD ($)
Stock Issued During Period, Shares, Issued for Services (in shares) | shares											1,951,541	1,448,512
Stock Issued During Period, Value, Issued for Services											$ 384,000	$ 291,000
Impairment, Long-Lived Asset, Held-for-Use											$ 394,000	197,000
Stock Issued During Period, Value, Commitment Fee												$ 0
Common Stock, Shares, Outstanding (in shares) | shares				278,462,706							292,945,747	278,462,706
Preferred Stock, Shares Outstanding (in shares) | shares				0							0	0
Warrants and Rights Outstanding	[1]										$ 18,000
Proceeds from Issuance of Preferred Stock and Preference Stock											$ 1,575,000	$ 225,000
Share Price (in dollars per share) | $ / shares											$ 0.17
Clyra Medical [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio		100
Impairment, Long-Lived Asset, Held-for-Use											$ 394,000	$ 197,000
Common Stock, Shares, Outstanding (in shares) | shares											10,000,749
Stock Issued During Period, Shares, New Issues (in shares) | shares											7,000
Proceeds from Issuance or Sale of Equity											$ 35,000
Shares Issued, Price Per Share (in dollars per share) | $ / shares					$ 3.1						$ 3.1
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | shares											191,981	182,908
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ / shares											$ 0.01	$ 0.4
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares) | shares											1,457,396
Clyra Medical [Member] | Employees and Consultants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | shares											191,981	182,908
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)											10 years
Clyra Medical [Member] | Employees and Consultants [Member] | Options With the Exercise Price of 1 Cent [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | shares											52,700
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares) | shares				159,700								159,700
Clyra Medical [Member] | Employees and Consultants [Member] | The Remaining Options [Member]
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ / shares											$ 2.71	$ 3.1
Clyra Medical [Member] | Employees and Consultants [Member] | Share-Based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount Rate											30%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum											3.48%	2.32%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum											4.45%	3.83%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate												49%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term (Year)												10 years
Clyra Medical [Member] | Vendors and Employees [Member] | Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Expense											$ 260,000	$ 408,000
Share Price (in dollars per share) | $ / shares				$ 3.1							$ 2.7	$ 3.1
Clyra Medical [Member] | Shares Issued for Debt Owed to Biolargo [Member]
Debt Conversion, Converted Instrument, Amount						$ 633,000
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares						204,223
Clyra Medical [Member] | Preferred Shares Issued for Debt Owed to Biolargo [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares			30,833	134,932
Debt Conversion, Original Debt, Amount			$ 96,000	$ 418,000
Clyra Medical [Member] | Warrants Expiring February 28, 2027 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares											3,500
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares											$ 7.5
Warrants and Rights Outstanding											$ 4,000
Clyra Medical [Member] | Warrants Issued in Conjunction With the Sale of Series A Preferred Stock [Member]
Warrants and Rights Outstanding											$ 410,000
Warrants and Rights Outstanding, Term (Month)											3 years
Shares Issued, Price Per Share (in dollars per share) | $ / shares											$ 3.72
Clyra Medical [Member] | Series A Preferred Stock [Member]
Preferred Stock, Shares Outstanding (in shares) | shares											746,418
Stock Issued During Period, Shares, New Issues (in shares) | shares					72,581						508,072
Warrants and Rights Outstanding					$ 55,000
Proceeds from Issuance of Preferred Stock and Preference Stock					$ 225,000						$ 1,575,000
Warrants and Rights Outstanding, Term (Month)					3 years
Shares Issued, Price Per Share (in dollars per share) | $ / shares					$ 3.72
Preferred Stock, Dividend Rate, Percentage					15%						15%
Preferred Stock, Convertible, Sale of Stock Amount											$ 5,000,000
Clyra Medical [Member] | Revolving Credit Facility [Member] | Vernal Bay Capital Group, LLC [Member] | Inventory Line of Credit [Member]
Debt Instrument, Interest Rate, Stated Percentage							15%
Line of Credit Facility, Maximum Borrowing Capacity							$ 1,000,000
Proceeds from Lines of Credit, Total							260,000
Repayments of Lines of Credit							$ 99,000
Line of Credit Facility, Covenant, Additional Draws, Maximum Percentage of Total Principal Outstanding Allowed							50%
Line of Credit Facility, Covenant, Additional Draws, Minimum Amount Allowed							$ 200,000
Debt Instrument, Term (Year)							1 year
Line of Credit Facility, Monthly Percentage of Gross Product Sales Required to be Used as Payment of Debt on First 180 Days							30%
Line of Credit Facility, Monthly Percentage of Gross Product Sales Required to be Used as Payment of Debt after the First 180 Days							60%
Stock Issued During Period, Shares, Commitment Fee (in shares) | shares							32,200
Stock Issued During Period, Value, Commitment Fee							$ 70,000
Debt Instrument, Percentage of Principal Payment, Cap											15%
Long-Term Line of Credit				$ 161,000							$ 134,000	$ 161,000
Clyra Medical [Member] | Notes Payable, Other Payables [Member]
Debt Instrument, Face Amount													$ 100,000
Debt Instrument, Interest Rate, Stated Percentage													8%
Debt Instrument, Convertible, Sale of Stock Amount													$ 5,000,000
Debt Instrument, Convertible, Conversion Percentage													70%
Clyra Medical [Member] | Beach House Consulting, LLC [Member]
Consulting Services, Monthly Payment									$ 23,000
Consulting Services, Period of Services (Year)								4 years
Stock Issued During Period, Shares, Issued for Services (in shares) | shares							3,639
Stock Issued During Period, Value, Issued for Services							$ 788,000
Consulting Services, Three Consecutive Month Average Revenue Threshold for Consulting Fees to Accrue							$ 250,000
Vernal Bay Capital Group, LLC [Member] | Conversion of Clyra Medical Stock Into Biolargo Common Stock [Member]
Stock Issued During Period, Shares, Commitment Fee (in shares) | shares										32,200
Conversion of Stock, Shares Issued (in shares) | shares										527,983
Clyra Medical [Member]
Subsidiary, Ownership Percentage, Parent											53%
Clyra Medical [Member] | Common Stock [Member]
Investment Owned, Balance, Shares (in shares) | shares											5,322,775
Clyra Medical [Member] | Preferred Stock, Series A [Member]
Investment Owned, Balance, Shares (in shares) | shares											165,765
[1]Aggregate intrinsic value based on closing common stock price of $0.17 at December 31, 2023.

Note 10 - Noncontrolling Inte_4

Note 10 - Noncontrolling Interest - Clyra Medical - Common Shares Outstanding (Details) - Clyra Medical [Member] - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Clyra options outstanding, balance (in shares)	1,583,329	1,400,421
Weighted average price, balance (in dollars per share)	$ 0.06	$ 0.01
Options outstanding, Granted (in shares)	191,981	182,908
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)	$ 0.01	$ 0.4
Options outstanding, Exercised (in shares)	(296,389)
Weighted average price, Exercised (in dollars per share)	$ 1.97
Clyra options outstanding, balance (in shares)	1,478,921	1,583,329
Weighted average price, balance (in dollars per share)	$ 0.31	$ 0.06
Balance, Weighted Average Remaining Term (Year)	7 years
Options outstanding, Non-vested (in shares)	(21,525)
Weighted average price, Unvested (in dollars per share)	$ 2.71
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)	1,457,396
Weighted average price, balance (in dollars per share)	$ 0.28

Note 10 - Noncontrolling Inte_5

Note 10 - Noncontrolling Interest - Clyra Medical - Summary of Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Accounts payable	$ 1,212	$ 717
Accrued payroll	251	198
Accrued interest	25	25
Accounts payable and accrued expenses, total	1,488	940
Clyra Medical [Member]
Accounts payable	135	186
Accrued payroll	7	45
Accrued dividend	242
Accrued interest	13	7
Accounts payable and accrued expenses, total	$ 397	$ 238

Note 11 - BioLargo Engineerin_2

Note 11 - BioLargo Engineering, Science and Technologies, LLC (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2018
Share-based Payment Arrangement, Noncash Expense, Total		$ 2,124,000	$ 2,071,000
Seven Employees Working at BioLargo Engineering, Science & Technologies, LLC [Member]
Deferred Compensation Arrangement with Individual, Requisite Service Period (Year)	5 years
Potential Ownership Percentage of Subsidiary Held by Subsidiary Employees Based on Performance	30%
Incentive Issuance Stipulations for Subsidiary Employees, Accounts Receivable Collected by Year One of Operation	90%
Incentive Issuance Stipulations for Subsidiary Employees, Profit Earned in Year One of Operation	10%
Percentage of Profits Interests Vested		22.50%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares (in shares)		1,750,500
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value		$ 17,000	$ 135,000
Seven Employees Working at BioLargo Engineering, Science & Technologies, LLC [Member] | Non-Qualified Stock Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)	1,750,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	5 years
Share-based Payment Arrangement, Noncash Expense, Total				$ 0
BioLargo Engineering, Science & Technologies, LLC [Member]
Subsidiary, Ownership Percentage, Parent	100%	82%

Note 12 - Business Segment In_3

Note 12 - Business Segment Information (Details Textual)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Number of Operating Segments	5	5

Note 12 - Business Segment In_4

Note 12 - Business Segment Information - Segment Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue	$ 12,230,000	$ 5,884,000
Research and development	(2,282,000)	(1,319,000)
Depreciation	103,000	45,000
Stock option expense	1,864,000	1,663,000
Operating income (loss)	(4,580,000)	(5,390,000)
Interest income (expense)	(91,000)	(53,000)
Net loss	(4,648,000)	(5,132,000)
Tangible assets	7,094,000	3,958,000
Operating Lease, Right-of-Use Asset	1,092,000	867,000
Investment in South Korean joint venture	19,000	33,000
Total	8,205,000	4,858,000
Investment in South Korean Joint Venture [Member]
Investment in South Korean joint venture	19,000	33,000
BioLargo Canada [Member]
Operating income (loss)	(695,000)	(714,000)
Corporate, Non-Segment [Member]
Revenue	0	5,000
Research and development	(764,000)	(674,000)
Depreciation	34,000	3,000
Stock option expense	260,000	408,000
Operating income (loss)	(3,320,000)	(3,971,000)
Interest income (expense)	(49,000)	(24,000)
Net loss	(3,369,000)	(3,995,000)
Tangible assets	942,000	669,000
Operating Lease, Right-of-Use Asset	394,000	136,000
Total	1,355,000	838,000
Corporate, Non-Segment [Member] | Investment in South Korean Joint Venture [Member]
Investment in South Korean joint venture	19,000	33,000
Operating Segments [Member]
Operating income (loss)	(4,580,000)	(5,390,000)
Operating Segments [Member] | Odor-No-More [Member]
Revenue	11,440,000	4,374,000
Research and development	(15,000)	0
Depreciation	21,000	3,000
Operating income (loss)	4,335,000	1,130,000
Interest income (expense)	(6,000)	0
Net loss	4,329,000	1,304,000
Tangible assets	4,624,000	2,064,000
Operating Lease, Right-of-Use Asset	0	0
Total	4,624,000	2,064,000
Operating Segments [Member] | Odor-No-More [Member] | Investment in South Korean Joint Venture [Member]
Investment in South Korean joint venture	0	0
Operating Segments [Member] | Clyra Medical [Member]
Tangible assets	432,000	631,000
Operating Lease, Right-of-Use Asset	0	0
Total	432,000	631,000
Operating Segments [Member] | Clyra Medical [Member] | Investment in South Korean Joint Venture [Member]
Investment in South Korean joint venture	0	0
Operating Segments [Member] | BLEST [Member]
Tangible assets	1,083,000	441,000
Operating Lease, Right-of-Use Asset	698,000	731,000
Total	1,781,000	1,172,000
Operating Segments [Member] | BLEST [Member] | Investment in South Korean Joint Venture [Member]
Investment in South Korean joint venture	0	0
Operating Segments [Member] | BioLargo Energy Technologies, Inc (BETI) [Member]
Research and development	(1,043,000)	0
Operating income (loss)	(1,179,000)	0
Net loss	(1,179,000)	0
Tangible assets	4,000	0
Operating Lease, Right-of-Use Asset	0	0
Total	4,000	0
Operating Segments [Member] | BioLargo Energy Technologies, Inc (BETI) [Member] | Investment in South Korean Joint Venture [Member]
Investment in South Korean joint venture	0	0
Operating Segments [Member] | BioLargo Canada [Member]
Revenue	30,000	1,000
Research and development	(526,000)	(565,000)
Net loss	(713,000)	(604,000)
Tangible assets	50,000	194,000
Operating Lease, Right-of-Use Asset	0	0
Total	50,000	194,000
Operating Segments [Member] | BioLargo Canada [Member] | Investment in South Korean Joint Venture [Member]
Investment in South Korean joint venture	0	0
Operating Segments [Member] | BioLargo Engineering, Science & Technologies, LLC [Member]
Revenue	2,397,000	1,943,000
Research and development	(1,256,000)	(469,000)
Depreciation	9,000	9,000
Operating income (loss)	(1,619,000)	(452,000)
Net loss	(1,619,000)	(425,000)
Operating Segments [Member] | Clyra Segment [Member]
Revenue	20,000	56,000
Research and development	(335,000)	(110,000)
Depreciation	39,000	30,000
Stock option expense	2,124,000	2,071,000
Operating income (loss)	(2,102,000)	(1,383,000)
Interest income (expense)	(36,000)	(29,000)
Net loss	(2,097,000)	(1,412,000)
Consolidation, Eliminations [Member]
Revenue	(1,657,000)	(495,000)
Research and development	1,657,000	499,000
Tangible assets	(41,000)	(41,000)
Operating Lease, Right-of-Use Asset	0	0
Total	(41,000)	(41,000)
Consolidation, Eliminations [Member] | Investment in South Korean Joint Venture [Member]
Investment in South Korean joint venture	$ 0	$ 0

Note 13 - Commitments and Con_3

Note 13 - Commitments and Contingencies (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating Lease, Expense	$ 335,000	$ 316,000
Operating Lease, Right-of-Use Asset	1,092,000	867,000
Operating Lease, Liability	$ 1,109,000	870,000
Operating Lease, Weighted Average Remaining Lease Term (Year)	7 years
Lessee, Operating Lease, Discount Rate	18%
Lessee, Operating Lease, Liability, to be Paid	$ 2,042,000
Westminster, California Facility Lease [Member]
Lessee, Operating Lease, Renewal Term (Year)	4 years
Operating Lease, Right-of-Use Asset	$ 394,000
Operating Lease, Liability	$ 394,000
Oak Ridge, Tennessee Facility Lease [Member]
Operating Lease, Right-of-Use Asset		$ 443,000
Operating Lease, Weighted Average Remaining Lease Term (Year)		10 years

Note 13 - Commitments and Con_4

Note 13 - Commitments and Contingencies - Minimum Lease Payments (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
December 31, 2024, operating lease	$ 276,000
December 31, 2025, operating lease	282,000
December 31, 2026, operating lease	289,000
December 31, 2027, operating lease	296,000
December 31, 2028, operating lease	245,000
Thereafter, operating lease	654,000
Total minimum lease payments, operating lease	2,042,000
Less imputed interest	(933,000)
Operating Lease, Liability	1,109,000	$ 870,000
BioLargo/ONM Lease [Member]
December 31, 2024, operating lease	122,000
December 31, 2025, operating lease	125,000
December 31, 2026, operating lease	129,000
December 31, 2027, operating lease	133,000
December 31, 2028, operating lease	79,000
Thereafter, operating lease	0
Total minimum lease payments, operating lease	588,000
BLEST Lease [Member]
December 31, 2024, operating lease	154,000
December 31, 2025, operating lease	157,000
December 31, 2026, operating lease	160,000
December 31, 2027, operating lease	163,000
December 31, 2028, operating lease	166,000
Thereafter, operating lease	654,000
Total minimum lease payments, operating lease	$ 1,454,000

Note 14 - Subsequent Events (De

Note 14 - Subsequent Events (Details Textual) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 29, 2024	Dec. 31, 2023	Dec. 31, 2022
Proceeds from Issuance of Common Stock		$ 2,153,000	$ 3,617,000
Clyra Medical [Member]
Stock Issued During Period, Shares, New Issues (in shares)		7,000
Proceeds from Issuance or Sale of Equity		$ 35,000
Subsequent Event [Member]
Stock Issued During Warrants, Shares, Warrants Exercised (in shares)	406,278
Proceeds from Warrant Exercises	$ 75,000
Subsequent Event [Member] | Clyra Medical [Member]
Stock Issued During Period, Shares, New Issues (in shares)	95,000
Proceeds from Issuance or Sale of Equity	$ 475,000
Subsequent Event [Member] | Clyra Medical [Member] | Clyra 2024 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	47,500
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 7.5
Lincoln Park Capital Fund, LLC [Member]
Stock Issued During Period, Shares, New Issues (in shares)		3,833,230	6,011,701
Proceeds from Issuance of Common Stock		$ 995,000	$ 1,253,000
Stock Issued for Financing Fee, Lincoln Park [Member] | Lincoln Park Capital Fund, LLC [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues (in shares)	806,175
Proceeds from Issuance of Common Stock	$ 260,000
Issuance to Five Accredited Investors [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues (in shares)	1,394,737
Proceeds from Issuance or Sale of Equity, Gross	$ 265,000
Proceeds from Issuance or Sale of Equity	$ 239,000